

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

METHODOLOGY

DESPATCHED ON 06TH MARCH 2018

SAMPLES 801-05/2018

Lab No.	HLA Diseases	Date received	Date tested	Method used								Source of Primers and Probes			Kit manufacturer	Detection method	Comments	
				A	B	C	DRB1	DRB3,4,5	DQA1	DQB1	DPA1	DPB1	Commercial Kits	Own Design				Other
11	Coeliac, Narcolepsy, Birdshot Retinopathy, Behcets		03-Apr	SSP/LUM	SSP/LUM									Yes	Yes	One Lambda	Gel, Fluorescence	
12	Coeliac, Behcets	08-Mar	21-Mar											Yes	Yes	In-house	Gel	
17	Coeliac, Narcolepsy	07-Mar	22-Mar											Yes		Olerup	Gel	
24	Narcolepsy						LUM							Yes		Olerup, Immucor	Gel, Fluorescence	
25	Coeliac, Narcolepsy, Actinic Prurigo, Birdshot Retinopathy, Behcets	12-Mar	13-Mar	SSOP	SSP/SSOP		SSP/SSOP							Yes		Innotrain, Immucor, Olerip	Fluorescence	
38	Coeliac, Narcolepsy, Actinic Prurigo, Birdshot Retinopathy, Behcets	08-Mar	13-Mar	LUM/NGS	LUM/NGS	LUM/NGS	LUM/NGS	LUM/NGS	LUM/NGS	LUM/NGS	LUM/NGS	LUM/NGS	LUM/NGS	Yes		One Lambda, Illumina	Fluorescence	
42	Coeliac, Narcolepsy, Actinic Prurigo, Birdshot Retinopathy, Behcets	09-Mar	13-Mar	LUM	LUM		LUM							Yes		One Lambda	Fluorescence	
78	Coeliac, Behcets	08-Mar	16-Mar											Yes		Olerup	Gel	
85	Coeliac	08-Mar	23-Mar															
86	Coeliac	07-Mar	16-Mar				LUM			LUM	LUM			Yes		Protrans	Gel	
109	Coeliac, Narcolepsy	07-Mar	13-Mar															
113	Coeliac, Narcolepsy, Diabetes, Rheumatoid Arthritis	07-Mar	12-Mar				LUM			LUM	LUM			Yes		One Lambda	Fluorescence	
123	Coeliac	13-Mar	12-Mar															
124	Coeliac	20-Mar	23-Mar						Microarray	Microarray				Yes		Euroimmun	Fluorescence	
126	Coeliac	12-Mar	19-Mar															
127	Coeliac, Narcolepsy	08-Mar	21-Mar											Yes		Euroimmun	Fluorescence	
129	Coeliac, Narcolepsy, Diabetes	08-Mar	20-Mar															
142	Coeliac	07-Mar	12-Mar				SSP	SSP	SSP	SSP	SSP	SSP	SSP	Yes		Linkage	Fluorescence	
150	Narcolepsy, Birdshot Retinopathy	06-Mar	08-Mar	LUM	LUM									Yes		One Lambda	Gel	
154	Coeliac, Narcolepsy, Birdshot Retinopathy	07-Mar	12-Mar				SSP	SSP	SSP	SSP				Yes				
159	Coeliac	08-Mar	14-Mar															
173	Coeliac	13-Mar	22-Mar															
185	Coeliac, Narcolepsy	07-Mar	12-Mar				LUM			LUM	SSP/SBT			Yes		Olerup, Protrans, Immucor	Gel, Fluorescence	
201	Coeliac	07-Mar	15-Mar															
219	Coeliac	15-Mar	20-Mar															
223	Coeliac, Narcolepsy	12-Mar	14-Mar							SSP	SSP			Yes		Olerup	Gel	
224	Coeliac	07-Mar	15-Mar							SSOP	SSOP			Yes		BAG	Coloured dots formed after specific hybridisation detected by CCD camera	
225	Coeliac	12-Mar	15-Mar							SSP	SSP			Yes		Olerup	Gel	
245	Coeliac, Narcolepsy, Birdshot Retinopathy, Diabetes	07-Mar	14-Mar	SSOP	SSOP		SSOP			SSOP	SSOP		SSP	Yes		Life Technologies, BAG		
255	Coeliac	08-Mar	19-Mar							qPCR	qPCR			Yes		AnDiaTec	Fluorescence	
263	Coeliac	13-Mar	19-Mar							RT-PCR	RT-PCR				Yes	In-house	Fluorescence	
269	Coeliac	07-Mar	21-Mar							SSOP	SSOP			Yes		Euroimmun	Fluorescence	
274	Coeliac	07-Mar	12-Mar				SSP	SSP	SSP	SSP	SSP			Yes		Operon Coeliac Strip		
276	Coeliac, Narcolepsy	07-Mar	14-Mar	SSP	SSP	SSP	SSP	SSP	SSP	SSP	SSP	SSP	SSP	Yes		Linkage Bioscience		
278	Coeliac	12-Mar	19-Mar															
279	Coeliac	07-Mar	13-Mar															
281	Coeliac, Narcolepsy	08-Mar	15-Mar															
307	Coeliac	20-Mar	15-Mar															
315	Coeliac, Narcolepsy, Birdshot Retinopathy	08-Mar	14-Mar	LUM	LUM		LUM			LUM	LUM			Yes		One Lambda		
317	Coeliac	12-Mar	15-Mar							Microarray	Microarray			Yes		Euroimmun	Microarray	
319	Coeliac	07-Mar	08-Mar															
331	Coeliac, Narcolepsy	08-Mar	14-Mar											Yes		BAG	Colourimetric	
333		12-Mar	27-Mar															
338	Coeliac	07-Mar	14-Mar															
339	Coeliac	07-Mar	21-Mar															
342	Coeliac	07-Mar	20-Mar															
347	Coeliac	13-Mar	14-Mar															
355	Coeliac	07-Mar	20-Mar															
359	Coeliac	08-Mar	16-Mar															
363	Coeliac	07-Mar	14-Mar															

* Methods used
SSP = PCR-SSP
SSOP = PCR-SSOP
revSSOP = reverse SSOP
LUM = Luminex
RT PCR = Real Time PCR

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

DESPATCHED ON 06TH MARCH 2018

SAMPLES 801-05/2018

Coeliac Disease results - Assessed

Labs 11 - 154

Reference Type For Assessment	801/2018	802/2018	803/2018	804/2018	805/2018		
DRB1*	04:01, 07:01/2A/72	03:01/124/132/137, 04:08	11:01/87, 15:01/141	01:03, 13:01/171/90/215	04:04, 11:01/87		
DQA1*	02:01, 03:03	03:03, 05:01	01:02/11, 05:05	01:03, 05:05	03:01, 05:05		
DOB1*	02:02, 03:01	02:01, 03:01	03:01, 06:02	03:01, 06:03	03:01, 03:02		
Lab No.	HLA Alleles of interest	801/2018	802/2018	803/2018	804/2018	805/2018	Comments
11	DQB1*02, 03:02	DQ2 Positive	DQ2 Positive	DQ2 and DQ8 Negative	DQ2 and DQ8 Negative	DQ8 Positive	
12	DQ2, DQ8, DQA1*05	DQ2: Positive DQ8: Negative DQA1*05: Negative	DQ2: Positive DQ8: Negative DQA1*05: Positive	DQ2: Negative DQ8: Negative DQA1*05: Positive	DQ2: Negative DQ8: Negative DQA1*05: Positive	DQ2: Negative DQ8: Positive DQA1*05: Positive	
17	HLA-DQA1*05:01, DQB1*02:01 (DQ2) HLA-DQA1*03, DQB1*03:02 (DQ8)	HLA-DQA1*05:01, DQB1*02:01 (DQ2) Negative, HLA-DQA1*03, DQB1*03:02 (DQ8) Negative	HLA-DQA1*05:01, DQB1*02:01 (DQ2) Positive, HLA-DQA1*03, DQB1*03:02 (DQ8) Negative	HLA-DQA1*05:01, DQB1*02:01 (DQ2) Negative, HLA-DQA1*03, DQB1*03:02 (DQ8) Negative	HLA-DQA1*05:01, DQB1*02:01 (DQ2) Negative, HLA-DQA1*03, DQB1*03:02 (DQ8) Negative	HLA-DQA1*05:01, DQB1*02:01 (DQ2) Negative, HLA-DQA1*03, DQB1*03:02 (DQ8) Positive	
25	DQB1*02:01 DQB1*02:02 DQB1*03:02 DQA1*02:01 DQA1*05:01	DQB1*02:02 DQB1*03:01 DQA1*02:01 DQA1*03:02/03 DQA1*05:01	DQB1*02:01 DQB1*03:01 DQA1*03:02/03 DQA1*05:01	DQB1*03:01 DQB1*06:02 DQA1*01:02 DQA1*05:05/09	DQB1*03:01 DQB1*06:03 DQA1*01:03 DQA1*05:05/09	DQB1*03:01 DQB1*03:02 DQA1*03:01 DQA1*05:05/09	
38	HLA-DQA1*05:01 and DQB1*02:01 (DQ2) (DQ2.5 haplotype) and/or DQB1*03:02 (DQ8) HLA- DRB1*07, DQA1*02:01, DQB1*02:02 (DQ 2.2 haplotype) and DRB1*11, DQA1*05:05, DQB1*03:01 DQA1*05:05, DQB1*03:01 (DQ7.5 haplotype)	HLA-DRB1*04:01, *07:01, HLA- DQB1*02:02, *03:01, DQA1*02:01, *03:03	HLA- DRB1*03:01, *04:08, HLA-DQB1*02:01, *03:01 HLA- DQA1*01:02, *03:05	HLA-DRB1*11:01, *15:01 HLA-DQB1*03:01, *06:02, HLA- DQA1*01:02, *05:05	HLA-DRB1*01:03, *13:01 HLA-DQB1*03:01, *06:03, HLA- DQA1*01:03, *05:05	HLA-DRB1*11:01, *04:04 HLA-DQB1*03:01, *03:02, HLA- DQA1*03:01, *05:05	
42	HLA-DQ	DQA1*02:01 DQA1*03:01/02/03/04 DQB1*02:01/11/2/26/5/02/62/65/80/84/89/95/97 DQB1*03:01/22/27/28/29/35/42/44/47/49/50/51/73/83/84N/92/93/94/114/115/116/165/169/182/191/196/197Q/198/206/241/242/243/246/252/254/266	DQA1*03:02/03/04 DQA1*05:01 DQB1*02:01/04/05/07/08/09/13/14/15/16/19/20N/21/22/23/24/25/27/28/29/30/31/33/34/35/36/37/38/39/40/41/42/43/44/45/46/47/49/50/51/52/53/54/55/56/58N/59/60/61/63/64/66/67N/68/69/70/71/72/73/74/77/78/79/82/83/85/86/87/88/90/91/92/93/96N/98/99/100/101/102/103/104/105/106/107/108/109/110/111/112/113/114/115/116/117/118/119/120/121/122/123/124/125/126/127/128/129/130/131/132/133/134/141/142/143/154/157/158/159/162/164/165/167/169/170/171/173/182/191/193/196/197Q/198/206/207/208/218/235/236/241/242/243/246/252/253/254/255/260/264/266/268	DQA1*01:02/08/09/11/16N DQA1*05:05/09/11 DQB1*03:01/22/27/28/29/35/42/44/47/49/50/51/73/83/84N/92/93/94/114/115/116/119/165/169/182/191/196/197Q/198/206/241/242/243/246/252/253/254/266 DQB1*06:02/47/84/107/109/111/113/114/115/116/117/118/119/120/121/22/23/24/25/26/28/237/240 88/200/216N/219/224/225/226/228/237/240	DQA1*01:03/10/14 DQA1*05:05/09/11 DQB1*03:01/22/27/28/29/35/42/44/47/49/50/51/73/83/84N/92/93/94/114/115/116/119/165/169/182/191/196/197Q/198/206/241/242/243/246/252/253/254/266 DQB1*03:02/07/32/37/45/62/63/64/67/68/70/74/81/85/106/107/113/125/146/161/174/175/178/179/184/185/189/190/199/203/204/205/211/213N/220/221/223/224/228/229/233/237N/240/245/247/251/265/269N	DQA1*03:01 DQA1*05:05/09/11 DQB1*03:01/04/11/42/122/27/28/29/35/42/44/47/49/50/51/73/80/83/84N/92/93/94/114/115/116/119/138/165/169/182/191/196/197Q/198/206/241/242/243/246/252/253/254/266 DQB1*03:02/07/32/37/45/62/63/64/67/68/70/74/81/85/106/107/113/125/146/161/174/175/178/179/184/185/189/190/199/203/204/205/211/213N/220/221/223/224/228/229/233/237N/240/245/247/251/265/269N	
78	HLA DQ2 and DQ8	DQ2 PRESENT (heterozygous) / DQ8 ABSENT	DQ2 and DQ8 ABSENT	DQ2 and DQ8 ABSENT	DQ2 ABSENT / DQ8 PRESENT		
85	DQ2	Negative for DQ2 and DQ8	Positive for DQ2	Negative for DQ2 and DQ8	Positive for DQ8		
86	DQ8						
88	DRB1*, DQA1*, DOB1*	DQB1*02:02, DQA1*02:01, DRB1*07	DQB1*02:01, DQA1*05:01, DRB1*03	DQ2 & DQ8 Absent	DQB1*03:02, DQA1*03, DRB1*04		
109	LinkSeqr HLA - DQ2, DQ8, DQA1*05 (Strip)	DQ 2.X / DQ X	DQ 2.5 / DQ X	DQ X.5 / DQ X	DQ X.5 / DQ X		
113	DQA1*03:01/DQB1*03:02, DQA1*05:01/DQB1*02:01, DQA1*05:05/DQB1*02:02	DQA1*02:01/DQB1*02, DQA1*03/DQB1*03:01	DQA1*03/DQB1*03:01, DQA1*05:01/DQB1*02:01	DQA1*01:02/DQB1*06:02, DQA1*05/DQB1*03	DQA1*01/DQB1*06:03, DQA1*05/DQB1*03:01	DQA1*03:01/DQB1*03:02/07, DQA1*05/DQB1*03	
123	DRB1* DQB1*	DRB1*04 DRB1*07 DQB1*02 DQB1*03:01	DRB1*03:01 DRB1*04 DQB1*02 DQB1*03:01	DRB1*11 DRB1*15 DQB1*03:01 DQB1*06	DRB1*01:03 DRB1*13 DQB1*03:01 DQB1*06	DRB1*04 DRB1*11 DQB1*03:01 DQB1*03:02	
124	DQ2 and DQ8	HLA-DQ2.2 positive	HLA-DQ2.5 positive	No HLA-DQ2 or DQ8	No HLA-DQ2 or DQ8	HLA-DQ8 positive	
126	DQ2.5 (DQA1*05, DQB1*02) DQ2.2 (DQA1*02, DQB1*02) DQ8 (DQA1*03, DQB1*03:02)	DQ2.5: Negative (A05 positive, B02 positive) DQ2.2: Positive (A02 positive, B02 positive) DQ8: Negative (A03 positive, B0302 negative)	DQ2.5: Positive (A05 positive, B02 positive) DQ2.2: Negative (A02 negative, B02 negative) DQ8: Negative (A03 positive, B0302 negative)	DQ2.5: Negative (A05 positive, B02 negative) DQ2.2: Negative (A02 negative, B02 negative) DQ8: Negative (A03 negative, B0302 negative)	DQ2.5: Negative (A05 positive, B02 negative) DQ2.2: Negative (A02 negative, B02 negative) DQ8: Negative (A03 negative, B0302 negative)	DQ2.5: Negative (A05 positive, B02 negative) DQ2.2: Negative (A02 negative, B02 negative) DQ8: Positive (A03 positive, B0302 positive)	
127	HLA-DQ2.2 HLA-DQ2.5 HLA-DQ8	HLA-DQ2.2 positive HLA-DQ2.5 negative HLA-DQ8 negative	HLA-DQ2.2 negative HLA-DQ2.5 positive HLA-DQ8 negative	HLA-DQ2.2 negative HLA-DQ2.5 negative HLA-DQ8 negative	HLA-DQ2.2 negative HLA-DQ2.5 negative HLA-DQ8 negative	HLA-DQ2.2 negative HLA-DQ2.5 negative HLA-DQ8 positive	
129	DQA1*05 DQB1*02 DQB1*0302	DQB1*02	DQA1*05 DQB1*02	No risk alleles	No risk alleles	DQB1*0302	
142	DQB1*02 DQB1*03:02 (DQ8)	DQB1*02 present DQB1*03:02 (DQ8) absent	DQB1*02 present DQB1*03:02 (DQ8) absent	DQB1*02 absent DQB1*03:02 (DQ8) absent	DQB1*02 absent DQB1*03:02 (DQ8) absent	DQB1*02 absent DQB1*03:02 (DQ8) present	
150	DQA1*05 Presence or absence of allele DQA1*05:01, DQB1*02:01 Presence or absence of allele DQA1*03:01, DQB1*03:02	DQA1*05 absent	DQA1*05 present	DQA1*05 present	DQA1*05 present	DQA1*05 present	
154	HLA-DQA1*, and HLA-DQB1* are typed to the 4 digits level to determine whether HLA-DQ2 is coded by DQA1*05:01, DQB1*02:01; HLA-DQ2 is coded by DQA1*05:05, DQB1*03:01 and DQA1*02:01, DQB1*02:02; HLA-DQ8 is coded by DQA1*03:01, DQB1*03:02	absence of allele DQA1*05:01, DQB1*02:01 and allele DQA1*03:01, DQB1*03:02	presence of allele DQA1*05:01, DQB1*02:01 and absence of allele DQA1*03:01, DQB1*03:02	absence of allele DQA1*05:01, DQB1*02:01 and allele DQA1*03:01, DQB1*03:02	absence of allele DQA1*05:01, DQB1*02:01 and allele DQA1*03:01, DQB1*03:02	absence of allele DQA1*05:01, DQB1*02:01 and presence of allele DQA1*03:01, DQB1*03:02	
		HLA-DQ typing : HLA-DQA1*02:01 ; DQA1*03:03 HLA-DQB1*02:02 ; DQB1*03:01	HLA-DQ typing : HLA-DQA1*03:03 ; DQA1*05:01 HLA-DQB1*02:01 ; DQB1*03:01	HLA-DQ typing : HLA-DQA1*01:02 ; DQA1*05:05 HLA-DQB1*03:01 ; DQB1*06:02	HLA-DQ typing : HLA-DQA1*03:01 ; DQA1*05:05 HLA-DQB1*03:01 ; DQB1*06:03	HLA-DQ typing : HLA-DQA1*03:01 ; DQA1*05:05 HLA-DQB1*03:01 ; DQB1*03:02	
		Result : haplotype DQA1*05:01, DQB1*02:01 : absence haplotypes DQA1*05:05, DQB1*03:01 and haplotype DQA1*03:01, DQB1*03:02 : absence	Result : haplotype DQA1*05:01, DQB1*02:01 : presence haplotypes DQA1*05:05, DQB1*03:01 and DQA1*02:01, DQB1*02:02 : absence haplotype DQA1*03:01, DQB1*03:02 : absence	Result : haplotype DQA1*05:01, DQB1*02:01 : absence haplotypes DQA1*05:05, DQB1*03:01 and DQA1*02:01, DQB1*02:02 : absence haplotype DQA1*03:01, DQB1*03:02 : absence	Result : haplotype DQA1*05:01, DQB1*02:01 : absence haplotypes DQA1*05:05, DQB1*03:01 and DQA1*02:01, DQB1*02:02 : absence haplotype DQA1*03:01, DQB1*03:02 : absence	Result : haplotype DQA1*05:01, DQB1*02:01 : absence haplotypes DQA1*05:05, DQB1*03:01 and DQA1*02:01, DQB1*02:02 : absence haplotype DQA1*03:01, DQB1*03:02 : presence	

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

DESPATCHED ON 06TH MARCH 2018

SAMPLES 801-05/2018

Coeliac Disease results - Assessed

Labs 159-278

Lab No.	Reference Type For Assessment	801/2018		802/2018		803/2018		804/2018		805/2018		Comments
		DRB1* DQA1* DOB1*	04:01, 07:01,24/72 02:01, 03:03 02:02, 03:01	03:01,124/132/137, 04:08 03:03, 05:01 02:01, 03:01	11:01/87, 15:01/141 01:02/11, 05:05 03:01, 06:02	01:03, 13:01/177/190/215 01:03, 05:05 03:01, 06:03	04:04, 11:01/87 03:01, 05:05 03:01, 03:02					
159	HLA Alleles of interest DQA1*05:01/05; DQA1*03:01/02/03 DQB1*02:01/02; DQB1*03:02	DQA1*02:01, *03:01-03 DQB1*02:01-02, *03:01	DQA1*03:02-03, *05:01 DQB1*02:01, *03:01	DQA1*01:01-05, *05:05 DQB1*03:01, *05:01	DQA1*01:01-05, *05:05 DQB1*03:01, *05:01	DQA1*03:01, *05:05 DQB1*03:01, *03:02						
173	DQA1*05 DQB1*02 DQA1*03 DQB1*03:02 DQB1*03:03	DQA1*05: NEGATIVE DQB1*02: POSITIVE DQA1*03: POSITIVE DQB1*03:02: NEGATIVE DQB1*03:03: NEGATIVE	DQA1*05: POSITIVE DQB1*02: POSITIVE DQA1*03: POSITIVE DQB1*03:02: NEGATIVE DQB1*03:03: NEGATIVE FINAL CONCLUSION: DQ2 POSITIVE, HIGH RISK FOR CELIAC DISEASE	DQA1*05: POSITIVE DQB1*02: NEGATIVE DQA1*03: NEGATIVE DQB1*03:02: NEGATIVE DQB1*03:03: NEGATIVE	DQA1*05: POSITIVE DQB1*02: NEGATIVE DQA1*03: NEGATIVE DQB1*03:02: NEGATIVE DQB1*03:03: NEGATIVE	DQA1*05: POSITIVE DQB1*02: NEGATIVE DQA1*03: POSITIVE DQB1*03:02: POSITIVE DQB1*03:03: NEGATIVE FINAL CONCLUSION: DQ8 POSITIVE, THE PATIENT HAS AN INCREASED RISK FOR CELIAC DISEASE, IF THERE IS FAMILY HISTORY OF THE DISEASE						
185	DQB1*02:01, 02:02, 03:02 and DQA1*03, 05:01, 05:05	DRB1*04, DRB1*07, DQA1*02:01, DQA1*03:02, DQB1*02:02, DQB1*03:01	DRB1*03, DRB1*04, DQA1*03:02, DQA1*05:01, DQB1*02:01, DQB1*03:01	DRB1*11, DRB1*15, DQA1*01:02, DQA1*05:05, DQB1*03:01, DQB1*06:02	DRB1*01, DRB1*13, DQA1*01:03, DQA1*05:05, DQB1*03:01, DQB1*06:03							
201	DQB1 DQA1	DQB1*02:02; DQB1*03:01 DQA1*02:01; DQA1*03:XX	DQB1*02:01; DQB1*03:01 DQA1*03:XX; DQA1*05:01	DQB1*03:01; DQB1*06:XX DQA1*01:XX; DQA1*05:XX	DQB1*03:01; DQB1*06:XX DQA1*01:XX; DQA1*05:XX							
219	HLA-DQB1*03:02 HLA-DQA1*05 HLA-DQB1*02 HLA-DQA1*02	DQB1*03:02: negative DQA1*05: negative DQB1*02: positive DQA1*02: positive	DQB1*03:02: negative DQA1*05: positive DQB1*02: positive DQA1*02: negative	DQB1*03:02: negative DQA1*05: positive DQB1*02: negative DQA1*02: negative	DQB1*03:02: negative DQA1*05: positive DQB1*02: negative DQA1*02: negative							
		Reported serotype: DQ2.2	Reported serotype: DQ2.5	Reported serotype: DQ2.5	Reported serotype: DQ7.5							
223	DQA1*02,03,05 DQB1*02, 03,03:02	DQA1*02 positive DQA1*03 positive DQA1*05 negative DQB1*02 positive DQB1*03:02 negative	DQA1*02 negative DQA1*03 positive DQA1*05 positive DQB1*02 positive DQB1*03:02 negative	DQA1*02 negative DQA1*03 negative DQA1*05 positive DQB1*02 negative DQB1*03:02 negative	DQA1*02 negative DQA1*03 negative DQA1*05 positive DQB1*02 negative DQB1*03:02 negative							
224	DQA1*05, DQB1*02, DQB1*03:02	DQA1*05: Negative DQ2 (DQB1*02): Positive DQ8 (Group DQB1*03:02): Negative	DQA1*05: Positive DQ2 (DQB1*02): Positive DQ8 (Group DQB1*03:02): Negative	DQA1*05: Positive DQ2 (DQB1*02): Negative DQ8 (Group DQB1*03:02): Negative	DQA1*05: Positive DQ2 (DQB1*02): Negative DQ8 (Group DQB1*03:02): Negative							
225	DQA1*02 DQA1*03 DQA1*05 DQB1*02 DQB1*03:02	DQ2-positive DQ8-negative	DQ2-positive DQ8-negative	DQ2-negative DQ8-negative	DQ2-negative DQ8-negative							
245	DQA1 DQB1	DQA1*02,*03 DQB1*02,*03(serological equivalent DQ7)	DQA1*03,*05 DQB1*02,*03(serological equivalent DQ7)	DQA1*01,*05 DQB1*03(serological equivalent DQ7)*06	DQA1*01,*05 DQB1*03(serological equivalent DQ7)*06							
255	HLA-DQA1*05 HLA-DQB1*02 HLA-DQB1*03:02	HLA-DQ2: NEG HLA-DQ8: NEG	HLA-DQ2: POS HLA-DQ8: NEG	HLA-DQ2: NEG HLA-DQ8: NEG	HLA-DQ2: NEG HLA-DQ8: NEG							
263	DQA1*02/01 DQA1*03 DQA1*05 DQB1*02 (heterozygous or homozygous) DQB1*03:02	detected: DQA1*02/01 DQA1*03 DQA1*05 DQB1*02 (heterozygous)	detected: DQA1*03 DQA1*05 DQB1*02 (heterozygous)	detected: DQA1*03 DQA1*05 DQB1*02 (heterozygous)	detected: DQA1*05 DQB1*02 (heterozygous)							
269	HLA-DQA1*02, DQA1*02/03:01, DQA1*03:02/03, DQA1*05, DQB1*02, DQB1*03:02	DQA1*02: Positive DQA1*03: Positive DQA1*02/03:01: Positive DQA1*03:02/03: Positive DQA1*05: Negative DQB1*02: Positive DQB1*03:02: Negative	DQA1*02: Negative DQA1*03: Positive DQA1*02/03:01: Negative DQA1*03:02/03: Positive DQA1*05: Positive DQB1*02: Positive DQB1*03:02: Negative	DQA1*02: Negative DQA1*03: Negative DQA1*02/03:01: Negative DQA1*03:02/03: Negative DQA1*05: Positive DQB1*02: Negative DQB1*03:02: Negative	DQA1*02: Negative DQA1*03: Negative DQA1*02/03:01: Negative DQA1*03:02/03: Negative DQA1*05: Positive DQB1*02: Negative DQB1*03:02: Negative							
274	HLA DQ2cis, HLA DQ2 trans, HLA DQ2 trans Haplotype 1, HLA DQ2 trans Haplotype 2, HLA DQ8	HLA DQ2 trans Haplotype 2 Carrier (detected: DQA1*02, DQB1*02, DRB1*07)	DQ2 cis (detected: DQA1*05, DQB1*02, DRB1*03)	DQ2 trans Haplotype 1 Carrier (detected: DQA1*05, DQB1*03/01, DRB1*11)	No specific coeliac disease predicting haplotype detected							
276	HLA-DQB1*02 HLA-DQB1*03:02 HLA-DQA1*05	HLA-DQB1*02 Positiv HLA-DQB1*03:02 Negativ HLA-DQA1*05 Negativ	HLA-DQB1*02 Positiv HLA-DQB1*03:02 Negativ HLA-DQA1*05 Positiv	HLA-DQB1*02 Negativ HLA-DQB1*03:02 Negativ HLA-DQA1*05 Positiv	HLA-DQB1*02 Negativ HLA-DQB1*03:02 Negativ HLA-DQA1*05 Positiv							
278	1. Alfa-subunit HLA DQ2.2 2. Alfa-subunit HLA DQ2.5 3. Alfa-subunit HLA DQ8 (DQA1*03:01/02/03) 4. Beta-subunit HLA DQ2.2/2.5 5. Beta-subunit HLA DQ8 6. HLA DQ2.2 genotype 7. HLA DQ2.5 genotype 8. HLA DQ8 genotype	1. positive 2. negative 3. positive 4. positive 5. positive 6. positive 7. negative 8. positive	1. negative 2. positive 3. positive 4. positive 5. negative 6. negative 7. positive 8. negative	1. negative 2. positive 3. negative 4. negative 5. negative 6. negative 7. negative 8. negative	1. negative 2. positive 3. negative 4. negative 5. negative 6. negative 7. negative 8. negative							

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

DESPATCHED ON 06TH MARCH 2018

SAMPLES 801-05/2018

Coeliac Disease results - Assessed

Labs 279-363

Reference Type For Assessment	801/2018	802/2018	803/2018	804/2018	805/2018	Comments	
DRB1*	04:01, 07:01/24/72	03:01/124/132/137, 04:08	11:01/87, 15:01/141	01:03, 13:01/117/190/215	04:04, 11:01/87		
DQA1*	02:01, 03:03	03:03, 05:01	01:02/11, 05:05	01:03, 05:05	03:01, 05:05		
DOB1*	02:02, 03:01	02:01, 03:01	03:01, 06:02	03:01, 06:03	03:01, 03:02		
Lab No.	HLA Alleles of interest	801/2018	802/2018	803/2018	804/2018	805/2018	Comments
279	DRB1 *03, *04, *07, *11 DOB1 *02:01, *02:02, *02:03, *02:05, *02:06, *02:07, *03:01, *03:02, *03:03, *04:02, *05:01, *05:02, *05:03, *06:01, *06:02, *06:03 DQA1 *02:01, *03:01 *05:05	DRB1 *04, *07, DOB1 *02:02, *03:01 DQA1 *03:01, *05:01	DRB1 *03, *04 DOB1 *02:01, *03:01 DQA1 *03:01, *05:01	DRB1 *11 DOB1 *03:01, *06:02 DQA1 *05:05	DRB1 *04, *11 DOB1 *03:01, *03:02 DQA1 *05:05		
281	DOB1*02, DQB1*03, DQA1*02, DQA1*03, DQA1*05.	Positive association with coeliakie (DQA1*02:01-DQB1*02:02 type).	Positive association with coeliakie (DQA1*05:01-DQB1*02:01 type)	No well-known association with coeliakie.	No well-known association with coeliakie.	Positive association with coeliakie (DQA1*03:01-DQB1*03:02 type).	
307	HLA-DQA1 HLA-DQB1	DQA1*02:01,*03:03 DQB1*02,*03	DQA1*03:03,*05:01 DQB1*02,*03	DQA1*01,*05 DQB1*03,*06	DQA1*01,*05 DQB1*03,*06	DQA1*03:01,*05 DQB1*03,*03:02	
315	DQ 2 DQ 8	DQB1*02, *03:01	DQB1*02, *03:01	DQB1*03:01, *06	DQB1*03:01, *06	DQB1*03:01, *03:02	
317	HLA-DQA1 and HLA-DQB1 alleles	Positive for HLA-DQ2.2. Negative for HLA-DQ2.5 Negative for HLA-DQ8	Negative for HLA-DQ2.2 Positive for HLA-DQ2.5 Negative for HLA-DQ8	Negative for HLA-DQ2.2 Negative for HLA-DQ2.5 Negative for HLA-DQ8	Negative for HLA-DQ2.2 Negative for HLA-DQ2.5 Negative for HLA-DQ8	Negative for HLA-DQ2.2 Negative for HLA-DQ2.5 Positive for HLA-DQ8	8 01/2018: In the European guidelines for coeliac disease diagnostics, only the subtype HLA-DQ2.5 is being specified as being disease-associated. Other studies show that the subtype HLA-DQ2.2 can also be associated with coeliac disease. The beta-subunit of DQ8 could not be clearly detected in this case. HLA-DQA1*03:01, which solely represents the alpha-subunit of DQ8 according to the ESPGHAN guidelines was not detected in the sample. However, HLA-DQA1*03:02 and/or HLA-DQA1*03:03 were detected in the sample. According to an extended definition, the presence of DQ8 cannot be entirely ruled out in this case.
319	DQA1*05, DQB1*02, DQB1*0302	DQ2: NEG DQ8: NEG	DQ2: POS DQ8: NEG	DQ2: NEG DQ8: NEG	DQ2: NEG DQ8: NEG	DQ2: NEG DQ8: POS	
331	DQB1*02:01, DQB1*03:02	DQB1*02:02, DQB1*03:01/03:13	DQB*02:01, DQB1*03:01/03:13	DQB1*03:01/03:13, DQB1*06:02	DQB1*03:01/03:13, DQB1*06:03	DQB1*03:01/03:13, DQB1*03:02 or DQB1*03:02, DQB1*03:19	
333	DQA1*05, DQA1*02, DGA1*03, DQB1*02, DQB1*0301, DQB1*0302, DRB1*03, DRB1*11, DRB1*12, DRB1*07, DRB1*04	DQA1*02, DQA1*03, DQB1*02,DQB1*0301, DRB1*07, DRB1*04	DQA1*05, DQA1*03, DQB1*02, DQB1*0301, DRB1*03, DRB1*04	DQA1*05, DQB1*0301, DRB1*11	DQA1*05, DQB1*0301	DQA1*05, DQA1*03, DQB1*0301, DQB1*0302, DRB1*11, DRB1*04	
338	PROTRANS HLA Coeliac Disease Domino System Specificities: DQB1*02:01, *02:02, *03:01, *03:02, DQA1*02:01, *03:01, *05:01, *05:05, DRB1*03, *04, *07, *11	HLA alleles : DQB1*02:02,*03:01, DQA1*02:01,*03:02/03; DRB1*04,*07	HLA alleles : DQB1*02:01,*03:01, DQA1*03:02/03,*05:01; DRB1*03,*04	HLA alleles : DQB1*03:01; DQA1*05:05, DRB1*11	HLA alleles : DQB1*03:01; DQA1*05:05, DRB1*11	HLA alleles : DQB1*03:01,*03:02; DQA1*03:01,*05:05; DRB1*04,*11	
339	DQA105 DQB102 DQB10302	Found DQB102 positive, but a genetic predisposition for Coeliac disease is unlikely	Found DQA105 positive and DQB102 positive, therefore genotype: DQ2	Found DQA105 positive, but a genetic predisposition for Coeliac disease is unlikely	Found DQA105 positive, but a genetic predisposition for Coeliac disease is unlikely	Found DQA105 positive and DQB10302 positive, therefore genotype: DQ8	
342	DQA1*01, DQA1*02, DQA1*03, DQA1*04, DQA1*05, DQA1*06 DQB1*02, DQB1*03:01, DQB1*03:02, DQB1*03:03, DQB1*03:04, DQB1*03:05, DQB1*04, DQB1*05, DQB1*06, DQB1*06:02	DQA1*03 DQA1*02 DQB1*03:01 DQB1*02	DQA1*03 DQA1*05 DQB1*03:01 DQB1*02	DQA1*01 DQA1*05 DQB1*06:02 DQB1*03:01	DQA1*05 DQA1*01 DQA1*05 DQB1*03:01 DQB1*06	DQA1*03 DQA1*05 DQB1*03:02 DQB1*03:01	
347	HLA-DQA1 / HLA-DQB1	HLA-DQ2.5-negative HLA-DQ2.2-positive HLA-DQ8-negative	HLA-DQ2.5-positive HLA-DQ2.2-negative HLA-DQ8-negative	HLA-DQ2.5-negative HLA-DQ2.2-negative HLA-DQ8-negative	HLA-DQ2.5-negative HLA-DQ2.2-negative HLA-DQ8-negative	HLA-DQ2.5-negative HLA-DQ2.2-negative HLA-DQ8-positive	
355	HLA-DQ2.2 HLA-DQ2.5 HLA-DQ8	HLA-DQ2 detected	HLA-DQ2 detected	HLA-DQ2/DQ8 not detected	HLA-DQ2/DQ8 not detected	HLA-DQ8 detected	
359	DQA1*02, DQA1*03, DQA1*0302/03, DQB1*02	DQA1*02, DQA1*03, DQA1*0302/03, DQB1*02	DQA1*03, DQA1*0302/03, DQA1*05, DQB1*02	DQA1*05	DQA1*05	DQA1*02/0301, DQA1*03, DQA1*05, DQB1*02/0302	
363	DQA1*02; DQA1*02/*0301; DQA1*03; DQA1*0302/03; DQA1*05; DQB1*02; DQB1*02/*0302.	HLA DQ2: Present HLA DQ8: Absent	HLA DQ2: Present HLA DQ8: Absent	HLA DQ2: Absent HLA DQ8: Absent	HLA DQ2: Absent HLA DQ8: Absent	HLA DQ2: Absent HLA DQ8: Present	

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

DESPATCHED ON 06TH MARCH 2018

SAMPLES 801-05/2018

Coeliac Disease - interpretive comments (Not Assessed)

Lab No.	801/2018	802/2018	803/2018	804/2018	805/2018	Comments
11	The presence of HLA-DQ2 is associated with, but not diagnostic for, coeliac disease. HLA-DQ2 is present in about 21% of caucasians in the normal population	The presence of HLA-DQ2 is associated with, but not diagnostic for, coeliac disease. HLA-DQ2 is present in about 21% of caucasians in the normal population	Alleles known to be associated with coeliac disease (HLA-DQ* and DQ8(3)) not present	Alleles known to be associated with coeliac disease (HLA-DQ* and DQ8(3)) not present	The presence of HLA-DQ8 is associated with, but not diagnostic for, coeliac disease. HLA-DQ8 is present in about 10% of caucasians in the normal population	
12	This patient is negative for both the DQA1*05/DQB1*02 heterodimer and DQ8(DQB1*03:02) which are present in over 95% patients with coeliac disease. However, this patient is positive for DQB1*02, which comprises one half of the DQA1*05/DQB1*02 heterodimer, present in 2-5% of patients with coeliac disease. This genotype has been associated with genetic susceptibility for coeliac disease.	This genotype is associated with genetic susceptibility for coeliac disease.	This genotype is not associated with genetic susceptibility for coeliac disease.	This genotype is not associated with genetic susceptibility for coeliac disease.	This genotype is associated with genetic susceptibility for coeliac disease.	
17						
25	This patient is DQ2.2 positive, heterozygous. This patient is DQ2 positive which is associated with Coeliac Disease.	This patient is DQ2.5 positive, heterozygous. This patient is DQ2 positive which is associated with Coeliac Disease.	This patient is DQ2 and DQ8 negative.	This patient is DQ2 and DQ8 negative	This patient is DQ8 positive, heterozygous which is associated with Coeliac Disease	
38	This individual does not carry the HLA-DQ variants associated with Coeliac Disease.	This individual carries the DQA1*05:01, DQB1*02:01 (HLA-DQ2) variant associated with Coeliac Disease (High risk).	The individual carries DQA1*05:05 and DQB1*03:01 which have shown a weak association with Coeliac Disease (Very low risk).	The individual carries DQA1*05:05 and DQB1*03:01 which have shown a weak association with Coeliac Disease (Very low risk).	This individual carries the HLA-DQB1*03:02 (DQ8) variant that has an association with Coeliac Disease (High risk).	
42	This patient is Heterozygous POSITIVE for HLA-DQ2 (but is DQA1*05 NEGATIVE) and NEGATIVE for HLA-DQ8 (DQA1*03, DQB1*03:02). Patients with this genotype have a LOW RISK of predisposition to Coeliac disease	This patient is POSITIVE for HLA-DQ2 (DQA1*05, DQB1*02) and NEGATIVE for HLA-DQ8 (DQA1*03, DQB1*03:02). Patients with this genotype have a HIGH RISK of predisposition to Coeliac disease though other factors are likely involved	This patient is NEGATIVE for HLA-DQ2 (but is DQA1*05 POSITIVE) and NEGATIVE for HLA-DQ8 (DQA1*03, DQB1*03:02). Patients with this genotype have a LOW RISK of predisposition to Coeliac disease	This patient is NEGATIVE for HLA-DQ2 (but is DQA1*05 POSITIVE) and NEGATIVE for HLA-DQ8 (DQA1*03, DQB1*03:02). Patients with this genotype have a LOW RISK of predisposition to Coeliac disease	This patient is NEGATIVE for HLA-DQ2 (DQA1*05, DQB1*02) and POSITIVE for HLA-DQ8 (DQA1*03, DQB1*03:02). Patients with this genotype have a HIGH RISK of predisposition to Coeliac disease though other factors are likely involved	
78						
85	This individual does not have the HLA-DQ variants commonly associated with coeliac disease. This assay tests for the presence of HLA-DQ2 (DQA1*05/DQB1*02) and HLA-DQ8 (DQB1*03:02) which are found in more than 97% of patients with coeliac disease.	This individual has one of the HLA-DQ variants associated with coeliac disease. More than 97% of coeliac disease patients carry either HLA-DQ2 or HLA-DQ8. However, these variants are also present in approximately 40% of the general population and therefore whilst possession of the variant can support a diagnosis of coeliac disease it is not per se diagnostic of the condition.	This individual does not have the HLA-DQ variants commonly associated with coeliac disease. This assay tests for the presence of HLA-DQ2 (DQA1*05/DQB1*02) and HLA-DQ8 (DQB1*03:02) which are found in more than 97% of patients with coeliac disease.	This individual does not have the HLA-DQ variants commonly associated with coeliac disease. This assay tests for the presence of HLA-DQ2 (DQA1*05/DQB1*02) and HLA-DQ8 (DQB1*03:02) which are found in more than 97% of patients with coeliac disease.	This individual has one of the HLA-DQ variants associated with coeliac disease. More than 97% of coeliac disease patients carry either HLA-DQ2 or HLA-DQ8. However, these variants are also present in approximately 40% of the general population and therefore whilst possession of the variant can support a diagnosis of coeliac disease it is not per se diagnostic of the condition.	
86	HLA haplotype DQ2 associated with coeliac disease is PRESENT in this patient. However, this specific genotype when found alone has a weak association with coeliac disease and a diagnosis must be based upon the clinical symptoms, patient ethnicity and immunological results. This result increases the likelihood that this patient has coeliac disease, but it must be taken into account with other coeliac profile results.	HLA haplotype DQ2 associated with coeliac disease is PRESENT in this patient. This result increases the likelihood that this patient has coeliac disease.	HLA haplotypes of DQ2 and DQ8 associated with coeliac disease have NOT been detected in this patient.	HLA haplotypes of DQ2 and DQ8 associated with coeliac disease have NOT been detected in this patient	HLA haplotype of DQ8 associated with coeliac disease is PRESENT in this patient. This result increases the likelihood that this patient has coeliac disease.	We report the genotype always as a coeliac associated haplotype and so even though other detectable alleles are present (eg. 801 also has DQB1*03) we do not report these. The haplotypes are associated with the serology in relation to DQ2 and DQ8.
109	The patient has NO HLA-associated risk for Coeliac Disease.	The patient has an HLA-associated risk for Coeliac Disease.	The patient has NO HLA-associated risk for Coeliac Disease.	The patient has NO HLA-associated risk for Coeliac Disease.	The patient has an HLA-associated risk for Coeliac Disease.	
113	Absence of susceptibility haplotype for coeliac disease	Presence of one susceptibility haplotype for coeliac disease (DQA1*05:01/DQB1*02:01)	Absence of susceptibility haplotype for coeliac disease	Absence of susceptibility haplotype for coeliac disease	Presence of one susceptibility haplotype for coeliac disease (DQA1*03:01/DQB1*03:02)	
123	Moderated risk of CD(1/550) (DRB1*07, DQB1*02:02)	High risk of CD (1/30) (DRB1*03, DQ2,05 in CIS)	No risk of CD	No risk of CD	Moderated Risk of CD (1/289) (DRB1*04, DQB1*03:02)	
124	In the European guidelines for coeliac disease diagnostics, only the subtype HLA-DQ2.5 is specified as being disease-associated	In the European guidelines for coeliac disease diagnostics, only the subtype HLA-DQ2.5 is specified as being disease-associated				
126	The patient is positive for DQ2.2, this HLA type is associated with coeliac disease.	The patient is positive for DQ2.5, this HLA type is associated with coeliac disease.	The patient does not have any of the HLA antigen (DQ2.5, DQ2.2 or DQ8) associated with development of coeliac disease.	The patient does not have any of the HLA antigen (DQ2.5, DQ2.2 or DQ8) associated with development of coeliac disease.	The patient is positive for DQ8, this HLA type is associated with coeliac disease.	
127	Negative	Positive: Strong association DQB1*02:01/DQA1*05:01	Negative	Negative	Positive: strong association DQB1*03:02/DQB1*03:02	
129	Slightly increased risk	High risk genotype	Decreased risk genotype	Decreased risk genotype	Slightly increased risk	

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

DESPATCHED ON 06TH MARCH 2018

SAMPLES 801-05/2018

Coeliac Disease - interpretive comments (Not Assessed)

Lab No.	801/2018	802/2018	803/2018	804/2018	805/2018	Comments
142	Présence de l'allèle HLA-DQB1*02 (DQ2) mais absence des allèles HLA-DQA1*05 et DQB1*03:02 (DQ8). Risque faible de prédisposition à la maladie coéliquaie. Low risk	Présence des allèles HLA-DQB1*02 (DQ2) et DQA1*05 et absence de l'allèle HLA-DQB1*03:02 (DQ8). Risque élevé de prédisposition à la maladie coéliquaie. High risk	Absence de facteur génétique HLA (DQ2 et DQ8) associé à la maladie coéliquaie. No risk	Absence de facteur génétique HLA (DQ2 et DQ8) associé à la maladie coéliquaie. No risk	Présence de l'allèle HLA-DQB1*03:02 (DQ8) et absence de l'allèle HLA-DQB1*02 (DQ2). Risque modéré de prédisposition à la maladie coéliquaie. Moderate risk	
150						
154	The patient has HLA-DQ2 encoded by an haplotype not listed to be most at risk of coeliac disease. >95% of coeliac disease patients express HLA-DQ2 encoded by DQA1*05:01, DQB1*02:01 or DQA1*05:05, DQB1*03:01 and DQA1*02:01, DQB1*02:02. 5% of coeliac disease patients express HLA-DQ8 encoded by DQA1*03:01, DQB1*03:02. HLA-DQ2 or DQ8 are expressed in 30-40% of the Caucasian population. HLA typing has a good negative predictive value in the diagnosis of coeliac disease.	The patient has a susceptibility gene to coeliac disease (haplotype encoding HLA-DQ2) >95% of coeliac disease patients express HLA-DQ2 encoded by DQA1*05:01, DQB1*02:01 or DQA1*05:05, DQB1*03:01 and DQA1*02:01, DQB1*02:02. 5% of coeliac disease patients express HLA-DQ8 encoded by DQA1*03:01, DQB1*03:02. HLA-DQ2 or DQ8 are expressed in 30-40% of the Caucasian population. HLA typing has a good negative predictive value in the diagnosis of coeliac disease.	The diagnosis of coeliac disease is very unlikely due to absence of HLA-DQ2 and HLA-DQ8 antigens. >95% of coeliac disease patients express HLA-DQ2 encoded by DQA1*05:01, DQB1*02:01 or DQA1*05:05, DQB1*03:01 and DQA1*02:01, DQB1*02:02. 5% of coeliac disease patients express HLA-DQ8 encoded by DQA1*03:01, DQB1*03:02. HLA-DQ2 or DQ8 are expressed in 30-40% of the Caucasian population. HLA typing has a good negative predictive value in the diagnosis of coeliac disease.	The diagnosis of coeliac disease is very unlikely due to absence of HLA-DQ2 and HLA-DQ8 antigens. >95% of coeliac disease patients express HLA-DQ2 encoded by DQA1*05:01, DQB1*02:01 or DQA1*05:05, DQB1*03:01 and DQA1*02:01, DQB1*02:02. 5% of coeliac disease patients express HLA-DQ8 encoded by DQA1*03:01, DQB1*03:02. HLA-DQ2 or DQ8 are expressed in 30-40% of the Caucasian population. HLA typing has a good negative predictive value in the diagnosis of coeliac disease.	The patient has a susceptibility gene to coeliac disease (haplotype encoding HLA-DQ8). >95% of coeliac disease patients express HLA-DQ2 encoded by DQA1*05:01, DQB1*02:01 or DQA1*05:05, DQB1*03:01 and DQA1*02:01, DQB1*02:02. 5% of coeliac disease patients express HLA-DQ8 encoded by DQA1*03:01, DQB1*03:02. HLA-DQ2 or DQ8 are expressed in 30-40% of the Caucasian population. HLA typing has a good negative predictive value in the diagnosis of coeliac disease.	
159	Absence of a susceptibility phenotype for coeliac disease	Presence of a high risk susceptibility phenotype for coeliac disease	Absence of a susceptibility phenotype for coeliac disease	Absence of a susceptibility phenotype for coeliac disease	Presence of a risk susceptibility phenotype for coeliac disease	
173						
185						
201						
219	English translation: "HLA-DQ2.2 is detected in the form of HLA-DQB1*02 and HLA-DQA1*02. A small minority of coeliac patients has these alleles. The alleles are common in the general population. Coeliac disease is not likely. However, the test alone can not exclude coeliac disease."	English translation: "HLA-DQ2.5 is detected in the form of HLA-DQB1*02 and HLA-DQA1*05. Most coeliac patients have these alleles. The alleles are common in the general population. The test alone does not confirm coeliac disease, but makes diagnosis more probable."	English translation: "HLA-DQ7.5 is detected in the form of HLA-DQA1*05. A small minority of coeliac patients has this allele. The allele is common in the general population. Coeliac disease is not likely. However, the test alone can not exclude coeliac disease."	English translation: "HLA-DQ7.5 is detected in the form of HLA-DQA1*05. A small minority of coeliac patients has this allele. The allele is common in the general population. Coeliac disease is not likely. However, the test alone can not exclude coeliac disease."	English translation: "HLA-DQ8 is detected in the form of HLA-DQB1*03:02. HLA-DQB1*02 is not detected. Some coeliac patients have this allele. The allele is common in the general population. Coeliac disease is not very likely, but can not be excluded."	
223						
224	No risk	High risk	No risk	No risk	Intermediate risk	
225	The patient is DQ2.2-positive. Coeliac disease is associated with this HLA-type that present in 5% of the cases.	The patient is DQ2.5-positive. Coeliac disease is associated with this HLA-type that present in 90% of the cases.	The patient is DQ2-negative but have the alfa-chain (DQA1*05) that included in DQ2. Some such cases of coeliac disease have been reported	The patient is DQ2-negative but have the alfa-chain (DQA1*05) that included in DQ2. Some such cases of coeliac disease have been reported	The patient is DQ8-positive. Coeliac disease is associated with this HLA-type that present in 5% of the cases.	
245	Presence of DQB1*02 but it's not associated to DQA1*05. This phenotype confers a weak risk of coeliac disease.	Presence of the heterodimer DQA1*05/DQB1*02 (phenotype "DQ2.5"), at risk for coeliac disease.	Absence of the susceptibility alleles for coeliac disease. As a consequence, any risk of coeliac disease can almost be ruled out.	Absence of the susceptibility alleles for coeliac disease. As a consequence, any risk of coeliac disease can almost be ruled out.	Presence of DQ8, associated to a weak risk of coeliac disease.	
255						
263	The HLA-DQB1 * 02 allele is present in heterozygosis. This condition, although compatible with the presence of coeliac disease, has not been shown to significantly increase the risk of disease compared to the general population.	HLA-DQ2 research is positive (DQA1*05 - DQB1*02), compatible with coeliac disease. The HLA-DQB1*02 allele is present in heterozygosis.	The analysis documented the presence of alleles not compatible with HLA-DQ2 or HLA-DQ8 haplotypes. The development of coeliac disease is therefore highly unlikely.	The analysis documented the presence of alleles not compatible with HLA-DQ2 or HLA-DQ8 haplotypes. The development of coeliac disease is therefore highly unlikely.	HLA-DQ8 research is positive (DQA1*03 - DQB1*0302), compatible with coeliac disease.	
269	DQ2.2: Positive DQ2.5: Negative DQ8: Negative beta-subunit DQ2.2/DQ2.5: Positive	DQ2.2: Negative DQ2.5: Positive DQ8: Negative beta-subunit DQ2.2/DQ2.5: Positive	DQ2.2: Negative DQ2.5: Negative DQ8: Negative beta-subunit DQ2.2/DQ2.5: Negative	DQ2.2: Negative DQ2.5: Negative DQ8: Negative beta-subunit DQ2.2/DQ2.5: Negative	DQ2.2: Negative DQ2.5: Negative	
274	HLA DQ2 trans Haplotype 2 Carrier	DQ2 cis	DQ2 trans Haplotype 1 Carrier	No specific coeliac disease predicting haplotype detected	HLA DQ2 trans Haplotype 1 AND DQ8	
276	Associated with Coeliac Disease: Rarely	Associated with Coeliac Disease: yes	Associated with Coeliac Disease: Rarely	Associated with Coeliac Disease: rarely	Associated with Coeliac Disease: Yes	
278	The genotype is associated with the risk of developing coeliac disease.	The genotype is associated with the risk of developing coeliac disease.	Alfa-subunit HLA-DQ2.5 found as mono-allele, this entails low risk of developing coeliac disease.	Alfa-subunit HLA-DQ2.5 found as mono-allele, this entails low risk of developing coeliac disease.	The genotype is associated with the risk of developing coeliac disease.	

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

DESPATCHED ON 06TH MARCH 2018

SAMPLES 801-05/2018

Coeliac Disease - interpretive comments (Not Assessed)

Lab No.	801/2018	802/2018	803/2018	804/2018	805/2018	Comments
279	DRB1*07, DQB1*02:02 DQA1*02:01	DRB1*03 DQB1*02:01; DQA1*05:01	DRB1*11 DQB1*03:01; *06:02 DQA1*05:05	DQB1*03:01; *06:03 DQA1*05:05	DRB1*04 DQB1*03:02 DQA1*03:01	
	Alleles compatible with coelias disease	Alleles compatible with coelias disease	Alleles not compatible with coelias disease	Alleles not compatible with coelias disease	Alleles compatible with coelias disease	
281						
307	Comment: absence of DQ2 and DQ8 heterodimers, presence of beta chain of DQ2 dimer (DQB1*02 positive - DQA1*05 negative) DQ2 present	Comment: presence of DQ2 heterodimer (DQA1*05, DQB1*02), absence of DQB1*02 homozygous condition. DQ2 present	Comment: absence of HLA alleles associated to coeliac disease DQ2 and DQ8 not present	Comment: absence of HLA alleles associated to coeliac disease DQ2 and DQ8 not present	Comment: presence of DQ8 heterodimer (DQA1*03, DQB1*03:02). DQ 8 present	
315						
317						
319	Absence of DQB1*02:01 ; absence of DQB1*03:02	Presence of DQB1*02:01 ; absence of DQB1*03:02	Absence of DQB1*02:01 ; absence of DQB1*03:02	Absence of DQB1*02:01 ; absence of DQB1*03:02	Absence of DQB1*02:01 ; presence of DQB1*03:02	
333						
338	Presence of DQ2.2 (DR7-DQ2; DQA1*0201, DQB1*0202) haplotype in heterozygous state . This condition has been shown to confer a certain, but lower risk to coeliac disease.	Celiac disease predisposing HLA-DQ type in heterozygous state . The heterodimer DQ2 (DQA1*05.DQB1*02) presence is indicative of susceptibility to Celiac disease but it does not imply the development of the disease whose diagnosis must be verified by clinical methods. The specific coeliac disease risk varies depending on different haplotype combinations and might also depend on ethnicity and other factors .	Presence of HLA haplotype not associated with Celiac disease according to ESPGHAN guideline .	Presence of HLA haplotype not associated with Celiac disease according to ESPGHAN guideline .	Celiac disease predisposing HLA-DQ type. The presence of the heterodimer DQ8 (DQA1*03.DQB1*03:02) is indicative of susceptibility to Celiac disease but it does not imply the development of the disease whose diagnosis must be verified by clinical methods.The specific coeliac disease risk varies depending on different haplotype combinations and might also depend on ethnicity and other factors .	
339						
342	Hereditary risk of developing coeliac disease exists.	Hereditary risk of developing coeliac disease exists.	Hereditary risk of developing coeliac disease does not exist.	Hereditary risk of developing coeliac disease does not exist.	Hereditary risk of developing coeliac disease exists.	
347	Increased risk for the development of Coeliac Disease; determination of serological parameters or biopsy from the small intestine recommended.	Increased risk for the development of Coeliac Disease; determination of serological parameters or biopsy from the small intestine recommended.	Coeliac Disease almost certainly excluded; high negative predictive value	Coeliac Disease almost certainly excluded; high negative predictive value	Increased risk for the development of Coeliac Disease; determination of serological parameters or biopsy from the small intestine recommended.	
355	The patient has a genetic disposition to develop coeliac disease. Analysing for coeliac antibodies in plasma is recommended.	The patient has a genetic disposition to develop coeliac disease. Analysing for coeliac antibodies in plasma is recommended.	The patient has, with a very high probability (approx. 99%), not coeliac disease.	The patient has, with a very high probability (approx. 99%), not coeliac disease.	The patient has a genetic disposition to develop coeliac disease. Analysing for coeliac antibodies in plasma is recommended.	
359	The HLA DQ genotype reveal a possible coeliac disease associated with alleles that predispose to the disorder. Because 30% of the general population has one or more of the coeliac disease-associated alleles and only 3% of these individuals develop coeliac disease, presence of coeliac disease-associated HLA alleles is not diagnostic of coeliac disease; Is recommended to assess the levels of autoantibodies associated with coeliac disease. Is recommended to perform a genetic counseling	The HLA DQ genotype reveal a possible coeliac disease associated with alleles that predispose to the disorder. Because 30% of the general population has one or more of the coeliac disease-associated alleles and only 3% of these individuals develop coeliac disease, presence of coeliac disease-associated HLA alleles is not diagnostic of coeliac disease; Is recommended to assess the levels of autoantibodies associated with coeliac disease. Is recommended to perform a genetic counseling	The identified allele confers a very low risk to develop coeliac disease comparable as general population ACG Clinical Guidelines: Diagnosis and Management of Coeliac Disease Alberto Rubio-Tapia , MD 1 , Ivor D. Hill , MD 2 , Ciar á n P. Kelly , MD 3 , Audrey H. Calderwood , MD 4 and Joseph A. Murray , MD	The identified allele confers a very low risk to develop coeliac disease comparable as general population ACG Clinical Guidelines: Diagnosis and Management of Coeliac Disease Alberto Rubio-Tapia , MD 1 , Ivor D. Hill , MD 2 , Ciar á n P. Kelly , MD 3 , Audrey H. Calderwood , MD 4 and Joseph A. Murray , MD	The HLA DQ genotype reveal a possible coeliac disease associated with alleles that predispose to the disorder. Because 30% of the general population has one or more of the coeliac disease-associated alleles and only 3% of these individuals develop coeliac disease, presence of coeliac disease-associated HLA alleles is not diagnostic of coeliac disease; Is recommended to assess the levels of autoantibodies associated with coeliac disease. Is recommended to perform a genetic counseling	
	ACG Clinical Guidelines: Diagnosis and Management of Coeliac Disease Alberto Rubio-Tapia , MD 1 , Ivor D. Hill , MD 2 , Ciar á n P. Kelly , MD 3 , Audrey H. Calderwood , MD 4 and Joseph A. Murray , MD	ACG Clinical Guidelines: Diagnosis and Management of Coeliac Disease Alberto Rubio-Tapia , MD 1 , Ivor D. Hill , MD 2 , Ciar á n P. Kelly , MD 3 , Audrey H. Calderwood , MD 4 and Joseph A. Murray , MD			ACG Clinical Guidelines: Diagnosis and Management of Coeliac Disease Alberto Rubio-Tapia , MD 1 , Ivor D. Hill , MD 2 , Ciar á n P. Kelly , MD 3 , Audrey H. Calderwood , MD 4 and Joseph A. Murray , MD	
363						

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

RESULTS OF PARTICIPATING LABORATORIES

DESPATCHED ON 06TH MARCH 2018

SAMPLES 801-05/2018

Narcolepsy results - Assessed

Reference Type For Assessment	801/2018		802/2018		803/2018		804/2018		805/2018		Comments	
	DRB1*	DQA1*	DQB1*	DRB1*	DQA1*	DQB1*	DRB1*	DQA1*	DQB1*	DRB1*		DQA1*
Lab												
No.	HLA Alleles of interest	801/2018	802/2018	803/2018	804/2018	805/2018						
11	DQB1*06:02	DQB1*06:02 Negative	DQB1*06:02 Negative	DQB1*06:02 Positive	DQB1*06:02 Negative	DQB1*06:02 Negative						
17	HLA-DQB1*06:02	HLA-DQB1*06:02 - Negative	HLA-DQB1*06:02 - Negative	HLA-DQB1*06:02 - Positive	HLA-DQB1*06:02 - Negative	HLA-DQB1*06:02 - Negative						
24	DQB1*06:02	DQB1*02:02/06/10/11/12, *03:01/19/21/22/27/84N; DQA1*02:01, *03:02/03/04	DQB1*02:01/05/07/08/09/53Q, *03:01/19/21/22/24/84N; DQA1*03:02/03/04, *05:01	DQB1*03:01/10/19/21/22/84N, *06:02; DQA1*01:02/08/09/11/13/16N, *05:05/09/11	DQB1*03:01/10/19/21/22/84N, *06:03; DQA1*01:03/10/14, *05:05/09/11	DQB1*03:01/19/21/22/24/84N, *03:02/04/14/32/37/66N; DQA1*03:01, *05:05/09/11						
25	DQB1*06:02	HLA DQB1*06:02 negative	HLA DQB1*06:02 negative	HLA DQB1*06:02 positive	HLA DQB1*06:02 negative	HLA DQB1*06:02 negative						
38	DQB1*06:02	HLA-DQB1*02:02, *03:01	HLA-DQB1*02:01, *03:01	HLA-DQB1*02:01, *03:01	HLA-DQB1*03:01, *06:03	HLA-DQB1*03:01, *03:02						
42	HLA-DQB1*06:02	DQB1*02:02/11/12/26/50/62/65/80/84/89/95/97	DQB1*02:01/04/05/07/08/09/13/14/15/16/19/20N/21/22/23/24/25/27/28/29/30/31/33/34/35/3	DQB1*03:01/22/27/28/29/35/42/44/47/49/50/5	DQB1*06:03/41/44/90/110/148/185/218/221/223	DQB1*03:01/04/14/21/22/27/28/29/35/42/44/47/49/50/51/73/80/83/84N/92/93/94/114/115/116/119/165/1						
		DQB1*03:01/22/27/28/29/35/42/44/47/49/50/51/73/83/84N/92/93/94/114/115/116/165/169/182/191/196/197Q/198/206/241/242/243/246/252/254/266	6/37/38/39/40/41/42/43/44/45/46/47/49/52/53Q/55/56/58N/59/60/61/63/64/66/67N/68/69/70/71/72/73/74/76/78/79/82/83/85/86/87/88/90/91/92/93/96N/98/99/100/101	69/182/191/196/197Q/198/206/241/242/243/246/252/253/254/266	DQB1*03:01/22/27/28/29/35/42/44/47/79/50/51/73/83/84N/92/93/94/114/115/116/119/165/1	6/119/138/165/169/182/191/196/197Q/198/206/241/242/243/246/252/253/254/266						
		82/191/196/197Q/198/206/241/242/243/246/252/254/266	71/72/73/74/76/78/79/82/83/85/86/87/88/90/91/92/93/96N/98/99/100/101	116/117/125/127/188/200/216N/219/224/225/226/228/237/240	DQB1*03:01/21/22/24/27/28/29/35/42/44/47/48/49/50/51/52/53/54/55/56/57/59/60/69/71/73/75/77/82/83/84N/92/93/94/101/102/103/109/114/115/116/118N/120/122/127/129/131/134/142/143/154/157/158/159/162/164/165/167/169/170/171/173/182/191/193/196/197Q/198/206/207/208/218/235/236/241/242/243/246/252/253/254/255/260/264/266/268	4/81/85/106/107/113/125/146/161/174/175/178/179/184/185/189/190/199/203/204/205/211/213N/220/221/223/224/228/229/233/237N/240/245/247/251/265/269N						
86	DQA1*01:02/DQB1*06:02	DQA1*02:01/DQB1*02; DQA1*03/DQB1*03	DQA1*03/DQB1*03; DQA1*05:01/DQB1*02	DQA1*01:02/DQB1*06:02; DQA1*05/DQB1*03	DQA1*01/DQB1*06:03; DQA1*05/DQB1*03	DQA1*03:01/DQB1*03:02; DQA1*05/DQB1*03						
109	LinkSeq HLA - DQB1*06:02 DQA1*01:02 (Strip)	DQB1*06:02 negative	DQB1*06:02 negative	DQB1*06:02 positive	DQB1*06:02 negative	DQB1*06:02 negative						
113	DQA1*01:02/DQB1*06:02	DQA1*02:01/DQB1*02; DQA1*03/DQB1*03	DQA1*03/DQB1*03; DQA1*05:01/DQB1*02	DQA1*01:02/DQB1*06:02; DQA1*05/DQB1*03	DQA1*01/DQB1*06:03; DQA1*05/DQB1*03	DQA1*03:01/DQB1*03:02; DQA1*05/DQB1*03						
127	HLA-DQA1 01:02, HLA-DQB1 06:02, HLA-DRB1 15:01:01	DQB1*06:02 negative	DQB1*06:02 negative	DQB1*06:02 positive	DQB1*06:02 negative	DQB1*06:02 negative						
129	DQB1*0602	No risk alleles	No risk alleles	DQB1*0602	No risk alleles	No risk alleles						
150	Presence or absence of allele DQB1*06:02.	absence of alleles DQB1*06:02 and DQB1*06:03.	absence of alleles DQB1*06:02 and DQB1*06:03.	presence of allele DQB1*06:02 and absence of allele DQB1*06:03.	absence of allele DQB1*06:02 and presence of allele DQB1*06:03.	absence of alleles DQB1*06:02 and DQB1*06:03.						
154	HLA-DQB1*06:02	HLA-DQB1* typing : HLA-DQB1*02:02 ; DQB1*03:01	HLA-DQB1* typing : HLA-DQB1*02:01 ; DQB1*03:01	HLA-DQB1*03:01 ; DQB1*06:02	HLA-DQB1*03:01 ; DQB1*06:03	HLA-DQB1*03:01 ; DQB1*03:02						
		Result : Allele DQB1*06:02 : absence	Result : Allele DQB1*06:02 : absence	Result : Allele DQB1*06:02 : presence	Result : Allele DQB1*06:02 : absence	Result : Allele DQB1*06:02 : absence						
159	No results submitted											
185	DRB1*15:01, DQB1*06:02	DRB1*04, DRB1*07, DQA1*02:01, DQA1*03:02, DQB1*02:02, DQB1*03:01	DRB1*03, DRB1*04, DQA1*03:02, DQA1*05:01, DQB1*02:01, DQB1*03:01	DRB1*11, DRB1*15, DQA1*01:02, DQA1*05:05, DQB1*03:01, DQB1*06:02	DRB1*01, DRB1*13, DQA1*01:03, DQA1*05:05, DQB1*03:01, DQB1*06:03	DRB1*04, DRB1*11, DQA1*03:01, DQA1*05:05, DQB1*03:01, DQB1*03:02						
223	DQA1*01:02 DQB1*06:02	DQA1*01:02 negative DQB1*06:02 negative	DQA1*01:02 negative DQB1*06:02 negative	DQA1*01:02 positive DQB1*06:02 positive	DQA1*01:02 negative DQB1*06:02 negative	DQA1*01:02 negative DQB1*06:02 negative						
225	DQB1*06:02	DQB1*06:02-negative	DQB1*06:02-negative	DQB1*06:02-positive	DQB1*06:02-negative	DQB1*06:02-negative						
245	DRB1	DRB1*15:01: absence	DRB1*15:01: absence	DRB1*15:01: presence	DRB1*15:01: absence	DRB1*15:01: absence						
246	DQB1	DQB1*06:02: absence	DQB1*06:02: absence	DQB1*06:02: presence	DQB1*06:02: absence	DQB1*06:02: absence						
276	HLA-DQB1*06:02	HLA-DQB1*06:02 Negativ	HLA-DQB1*06:02 Negativ	HLA-DQB1*06:02 Positiv	HLA-DQB1*06:02 Negativ	HLA-DQB1*06:02 Negativ						
281	No results submitted											
315	DQB1*06:02	DQB1*03:01, *02	DQB1*03:01, *02	DQB1*03:01, *06:02	DQB1*03:01, *06:03	DQB1*03:01, *03:02						
331	DQB1*0602	DQB1*02:02, DQB1*03:01/03:13	DQB1*02:01, DQB1*03:01/03:13	DQB1*03:01/03:13, DQB1*06:02	DQB1*03:01/03:13, DQB1*06:03	DQB1*03:02, DQB1*03:19						

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

RESULTS OF PARTICIPATING LABORATORIES

DESPATCHED ON 06TH MARCH 2018

SAMPLES 801-05/2018

Narcolepsy - interpretive comments (Not Assessed)

Lab No.	801/2018	802/2018	803/2018	804/2018	805/2018	Comments
11	HLA-DQB1 allele known to be associated with Narcolepsy is not present	HLA-DQB1 allele known to be associated with Narcolepsy is not present	HLA-DQB1 allele known to be associated with, but not diagnostic for, Narcolepsy is present	HLA-DQB1 allele known to be associated with Narcolepsy is not present	HLA-DQB1 allele known to be associated with Narcolepsy is not present	
17	Negative	Negative	Positive	Negative	Negative	
24			Allele associated with Narcolepsy is present.			
25			The presence of a particular HLA antigen does not establish the diagnosis of any particular disease, but provides a probability statement for the possible existence of the disease in the patient.			
38	The patient does NOT carry the associated HLA alleles which confer susceptibility to narcolepsy.	The patient does NOT carry the associated HLA alleles which confer susceptibility to narcolepsy.	The patient carries DQB1*06:02 which confers susceptibility to narcolepsy.	The patient does NOT carry the associated HLA alleles which confer susceptibility to narcolepsy.	The patient does NOT carry the associated HLA alleles which confer susceptibility to narcolepsy	
42	This patient is HLA-DQB1*06:02 NEGATIVE. Narcolepsy is associated with the expression of the human leukocyte antigen (HLA) class II molecule DQB1*06:02.	This patient is HLA-DQB1*06:02 NEGATIVE. Narcolepsy is associated with the expression of the human leukocyte antigen (HLA) class II molecule DQB1*06:02.	This patient is HLA-DQB1*06:02 POSITIVE. Narcolepsy is associated with the expression of the human leukocyte antigen (HLA) class II molecule DQB1*06:02.	This patient is HLA-DQB1*06:02 NEGATIVE. Narcolepsy is associated with the expression of the human leukocyte antigen (HLA) class II molecule DQB1*06:02.	This patient is HLA-DQB1*06:02 NEGATIVE. Narcolepsy is associated with the expression of the human leukocyte antigen (HLA) class II molecule DQB1*06:02.	
86	Absence of susceptibility haplotype for narcolepsy	Absence of susceptibility haplotype for narcolepsy	Presence of one susceptibility haplotype for narcolepsy (DQA1*01:02/DQB1*06:02)	Absence of susceptibility haplotype for narcolepsy	Absence of susceptibility haplotype for narcolepsy	
109	The patient is negative for the Narcolepsia-associated HLA-allele DQB1*06:02.	The patient is negative for the Narcolepsia-associated HLA-allele DQB1*06:02.	The patient is POSITIVE for the Narcolepsia-associated HLA-allele DQB1*06:02.	The patient is negative for the Narcolepsia-associated HLA-allele DQB1*06:02.	The patient is negative for the Narcolepsia-associated HLA-allele DQB1*06:02.	
113	Absence of susceptibility haplotype for narcolepsy	Absence of susceptibility haplotype for narcolepsy	Presence of one susceptibility haplotype for narcolepsy (DQA1*01:02/DQB1*06:02)	Absence of susceptibility haplotype for narcolepsy	Absence of susceptibility haplotype for narcolepsy	
127						
129	No risk alleles	No risk alleles	Positive for DQB1*0602 risk allele	No risk alleles	No risk alleles	
150						
154	The HLA-DQB1*06:02 is found in 15-25% of the overall population and in 90-100% of narcolepsy patients.	The HLA-DQB1*06:02 is found in 15-25% of the overall population and in 90-100% of narcolepsy patients.	The HLA-DQB1*06:02 is found in 15-25% of the overall population and in 90-100% of narcolepsy patients.	The HLA-DQB1*06:02 is found in 15-25% of the overall population and in 90-100% of narcolepsy patients.	The HLA-DQB1*06:02 is found in 15-25% of the overall population and in 90-100% of narcolepsy patients.	The HLA-DQB1*06:02 is found in 15-25% of the overall population and in 90-100% of narcolepsy patients.
185	Negative	Negative	Positive	Negative	Negative	
223	The patient don't have the HLA-type associated with narcolepsy	The patient don't have the HLA-type associated with narcolepsy	The patient have the HLA-type associated with narcolepsy	The patient don't have the HLA-type associated with narcolepsy	The patient don't have the HLA-type associated with narcolepsy	
245	Absence of the susceptibility haplotype for narcolepsy.	Absence of the susceptibility haplotype for narcolepsy.	Presence of the susceptibility haplotype for narcolepsy at a heterozygous state.	Absence of the susceptibility haplotype for narcolepsy.	Absence of the susceptibility haplotype for narcolepsy.	
276						
281						
315	DQB1*06:02 not present	DQB1*06:02 not present	DQB1*06:02 present	DQB1*06:02 not present	DQB1*06:02 not present	
331	Absence of DQB1*06:02	Absence of DQB1*06:02	Presence of DQB1*06:02	Absence of DQB1*06:02	Absence of DQB1*06:02	

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

RESULTS OF PARTICIPATING LABORATORIES

DESPATCHED ON 06TH MARCH 2018

SAMPLES 801-05/2018

Actinic Prurigo results - Assessed

Reference Type For Assessment		801/2018	802/2018	803/2018	804/2018	805/2018	
DRB1*		04:01, 07:01/34/72	03:01/124/132/137, 04:08	11:01/97, 15:01/141	01:03, 13:01/117/190/215	04:04, 11:01/97	
Lab No.	HLA Alleles of interest	801/2018	802/2018	803/2018	804/2018	805/2018	Comments
25	DRB1*04:07	DRB1*04 DRB1*07	DRB1*03 DRB1*04	DRB1*11 DRB1*15	DRB1*01:03 DRB1*13	DRB1*04 DRB1*11	
38	DRB1*04:07	HLA-DRB1*04:01, *07:01	HLA-DRB1*03:01, *04:08	HLA-DRB1*11:01, *15:01	HLA-DRB1*01:03, *13:01	HLA-DRB1*04:04, *11:01	
42	DRB1*04:07	DRB1*04:01/04:33/04:38/04:72/04:7 6/04:111/04:112/04:117/04:119N/04: 127/04:130/04:135/04:139/04:151/04 :155/04:171/04:174/04:175/04:179/0 4:190/04:192/04:194/04:196/04:215/ 04:216/04:217/04:233 DRB1*07:01/07:03/07:05/07:07/07:0 9/07:10N/07:11/07:13/07:15/07:16/07 :17/07:18/07:19/07:21/07:24/07:25/0 7:26N/07:27/07:28/07:29/07:30/07:31 /07:32/07:33/07:34/07:35/07:38/07:4 0/07:41/07:42/07:43/07:46/07:47/07: 48/07:49/07:50/07:51/07:52/07:53/07 :55/07:56/07:58N/07:59/07:60/07:61/ 07:62/07:63/07:65/07:66/07:68N/07:7 2/07:73/07:74/07:75/07:77/07:78/07: 79	DRB1*03:01/03:06/03:13/03:18/03:1 47/03:50/03:51/03:55/03:56/03:58/03 :59/03:61/03:62/03:64/03:66/03:67N/ 03:68N/03:72/03:73/03:80/03:83/03:9 0/03:112/03:114/03:116/03:117/03:1 24/03:127/03:128/03:129/03:132/03: 134/03:136/03:137/03:139 DRB1*04:05/08/43/205	DRB1*11:01/11:12/11:15/11:24/11:2 62/11:66/11:72/11:75/11:81/11:90/11 :97/11:99/11:100/11:101/11:106/11:1 08/11:109/11:112/11:114/11:117/11: 121/11:126/11:133/11:140/11:141/11 :147/11:152/11:154/11:155/11:157/1 9/11:204/11:208/11:212/11:215 DRB1*15:01/15:06/15:09/15:13/15:1 6/15:20/15:22/15:24/15:32/15:36/15: 37/15:41/15:42/15:43/15:46/15:48/15 :51/15:52/15:53/15:55/15:56/15:59/1 5:61/15:62/15:64/15:65/15:67/15:72/ 15:75/15:76/15:77/15:79/15:81/15:83 /15:85/15:86/15:90/15:91/15:92/15:9 3/15:95/15:97/15:98/15:102/15:106/1 5:107/15:108/15:111/15:112/15:114/ 15:121/15:123/15:124/15:125/15:127 /15:129N/15:132/15:133/15:134N/15: 136/15:137N/15:138N/15:141/15:143 /15:144/15:145/15:146	DRB1*13:01/13:02/13:28/13:39/13:6 1/13:69/13:79/13:96/13:99/13:105/13 13:125/13:126/13:127/13:128/13:130 /13:131/13:141/13:142N/13:148/13:1 53/13:165/13:166/13:168/13:171/13: 13:209/13:210/13:211/13:212/13:213 /13:215/13:218/13:220/13:222/13:22 39/13:240	0/04:120N/04:121/04:149/04:157N/0 4:182/04:193/04:220/04:223/04:224 DRB1*11:01/11:12/11:15/11:24/11:2 7/11:28/11:29/11:39/11:49/11:61/11: 62/11:66/11:72/11:81/11:90/11:97/11 :99/11:100/11:101/11:106/11:108/11: 112/11:114/11:117/11:121/11:126/11 :133/11:140/11:141/11:147/11:152/1 1:154/11:155/11:157/11:158/11:162/ 11:166/11:169N/11:177/11:186/11:18 8/11:195/11:197/11:199/11:204/11:2 08/11:212/11:215	
159		No results submitted					

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

RESULTS OF PARTICIPATING LABORATORIES

DESPATCHED ON 06TH MARCH 2018

SAMPLES 801-05/2018

Actinic Prurigo - interpretive comments (Not Assessed)

Lab No.	801/2018	802/2018	803/2018	804/2018	805/2018	Comments
25	This patient is negative for the HLA DRB1*04:07 allele associated most strongly with Actinic Prurigo but is positive for HLA DRB1*04	This patient is negative for the HLA DRB1*04:07 allele associated most strongly with Actinic Prurigo but is positive for HLA DRB1*04	This patient is negative for HLA DRB1*04 alleles which are associated with Actinic Prurigo	This patient is negative for HLA DRB1*04 alleles which are associated with Actinic Prurigo	This patient is negative for the HLA DRB1*04:07 allele associated most strongly with Actinic Prurigo but is positive for HLA DRB1*04	
38	This patient does NOT carry HLA-DRB1*04:07, which confers susceptibility to Actinic Prurigo.	This patient does NOT carry HLA-DRB1*04:07, which confers susceptibility to Actinic Prurigo.	This patient does NOT carry HLA-DRB1*04:07, which confers susceptibility to Actinic Prurigo.	This patient does NOT carry HLA-DRB1*04:07, which confers susceptibility to Actinic Prurigo.	This patient does NOT carry HLA-DRB1*04:07, which confers susceptibility to Actinic Prurigo.	
42	This patient is HLA-DRB1*04:07 NEGATIVE. Actinic Prurigo is associated with the expression of the human leukocyte antigen (HLA) class II molecule DRB1*04:07	This patient is HLA-DRB1*04:07 NEGATIVE. Actinic Prurigo is associated with the expression of the human leukocyte antigen (HLA) class II molecule DRB1*04:07	This patient is HLA-DRB1*04:07 NEGATIVE. Actinic Prurigo is associated with the expression of the human leukocyte antigen (HLA) class II molecule DRB1*04:07	This patient is HLA-DRB1*04:07 NEGATIVE. Actinic Prurigo is associated with the expression of the human leukocyte antigen (HLA) class II molecule DRB1*04:07	This patient is HLA-DRB1*04:07 NEGATIVE. Actinic Prurigo is associated with the expression of the human leukocyte antigen (HLA) class II molecule DRB1*04:07	

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

RESULTS OF PARTICIPATING LABORATORIES

DESPATCHED ON 06TH MARCH 2018

SAMPLES 801-05/2018

Birdshot Retinopathy tests - Assessed

Lab No.	HLA Alleles of interest	Reference Type For Assessment		801/2018		802/2018		803/2018		804/2018		805/2018		Comments
		A	A	02:01/62/94/2/655, 24:02/35/2/553	01:01/2/34, 11:01	03:01, 24:02/35/2/553	02:01/62/94/2/655, -	03:01, 31:01/11:19						
11	A*29	802/2018	803/2018	804/2018	805/2018									
25	A*29	HLA-A*29 Negative	HLA-A*29 Negative	HLA-A*29 Negative	HLA-A*29 Negative									
38	HLA A*29	A*01 A*24	A*01 A*11	A*02	A*03 A*31									
42	A*29	HLA-A*01:01, *24:02	HLA-A*01:01, *11:01	HLA-A*02:01	HLA-A*03:01, *31:01									
150	Presence or absence of allele A*29.	absence of allele A*29.	absence of allele A*29.	absence of allele A*29.	absence of allele A*29.									No results submitted

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

RESULTS OF PARTICIPATING LABORATORIES

DESPATCHED ON 06TH MARCH 2018

SAMPLES 801-05/2018

Birdshot Retinopathy - interpretive comments (Not Assessed)

Lab						Comments
No.	801/2018	802/2018	803/2018	804/2018	805/2018	
11						
25	Patient is negative for the HLA A29 antigen which is associated with Birdshot Retinopathy	Patient is negative for the HLA A29 antigen which is associated with Birdshot Retinopathy	Patient is negative for the HLA A29 antigen which is associated with Birdshot Retinopathy	Patient is negative for the HLA A29 antigen which is associated with Birdshot Retinopathy	Patient is negative for the HLA A29 antigen which is associated with Birdshot Retinopathy	
38	This patient does NOT carry HLA-A*29, which confers susceptibility to Birdshot Chorioretinopathy.	This patient does NOT carry HLA-A*29, which confers susceptibility to Birdshot Chorioretinopathy.	This patient does NOT carry HLA-A*29, which confers susceptibility to Birdshot Chorioretinopathy.	This patient does NOT carry HLA-A*29, which confers susceptibility to Birdshot Chorioretinopathy.	This patient does NOT carry HLA-A*29, which confers susceptibility to Birdshot Chorioretinopathy.	
42	This patient is HLA-A*29 NEGATIVE. Birdshot retinochoroidopathy is associated with the expression of the human leukocyte antigen (HLA) class I molecule A*29.	This patient is HLA-A*29 NEGATIVE. Birdshot retinochoroidopathy is associated with the expression of the human leukocyte antigen (HLA) class I molecule A*29.	This patient is HLA-A*29 NEGATIVE. Birdshot retinochoroidopathy is associated with the expression of the human leukocyte antigen (HLA) class I molecule A*29.	This patient is HLA-A*29 NEGATIVE. Birdshot retinochoroidopathy is associated with the expression of the human leukocyte antigen (HLA) class I molecule A*29.	This patient is HLA-A*29 NEGATIVE. Birdshot retinochoroidopathy is associated with the expression of the human leukocyte antigen (HLA) class I molecule A*29.	
150						
245	Absence of A*29 allele. This allele is present in 85 to 95% of patients with Birdshot-like chorioretinopathy.	Absence of A*29 allele. This allele is present in 85 to 95% of patients with Birdshot-like chorioretinopathy.	Absence of A*29 allele. This allele is present in 85 to 95% of patients with Birdshot-like chorioretinopathy.	Absence of A*29 allele. This allele is present in 85 to 95% of patients with Birdshot-like chorioretinopathy.	Absence of A*29 allele. This allele is present in 85 to 95% of patients with Birdshot-like chorioretinopathy.	
315	A 29 not present	A 29 not present	A 29 not present	A 29 not present	A 29 not present	
331	Absence of A*29	Absence of A*29	Absence of A*29	Absence of A*29	Absence of A*29	

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

RESULTS OF PARTICIPATING LABORATORIES

DESPATCHED ON 06TH MARCH 2018

SAMPLES 801-05/2018

Behcet's Disease results - Assessed

Reference Type For Assessment	801/2018	802/2018	803/2018	804/2018	805/2018	
B*	44:02, 44:03	08:01/173, 51:01/193	07:02/61/161N, 51:01/193	27:05, 44:02	07:02/61/161N/271, 15:01	
Lab					Comments	
No.	HLA Alleles of interest					
11	B*51	HLA-B*51(5) Negative	HLA-B*51(5) Positive	HLA-B*51(5) Positive	HLA-B*51(5) Negative	
12	B*51	HLA B*51: Negative	HLA B*51: Positive	HLA B*51: Positive	HLA B*51: Negative	
25	B*51	B*44	B*08 B*51	B*07 B*51	B*07 B*15	
38	HLA-B*51	HLA-B*44:02, *44:03	HLA-B*08:01, *51:01	HLA-B*07:02, *51:01	HLA-B*27:05, *44:02	
42	B*51	B*44:02/44:02S/44:05/44:11/44:14/44:19N/44:23N/44:27/44:33/44:42/44:48/44:51/44:52N/44:53/44:58N/44:59/44:63/44:66/44:67/44:68/44:70/44:71/44:72/44:74/44:78/44:80/44:84/44:86/44:87/44:88/44:91/44:93/44:100/44:101/44:102/44:104/44:112/44:113/44:116/44:118/44:119/44:121/44:126/44:127/44:133/44:136/44:137/44:138Q/44:139/44:140/44:145/44:148/44:149N/44:151/44:152/44:162/44:168/44:170/44:171N/44:172/44:173/44:177/44:179/44:185/44:187/44:191/44:195N/44:196/44:200/44:201/44:206/44:208/44:211/44:212/44:214/44:216/44:217N/44:218/44:219/44:220/44:226/44:229/44:235/44:238/44:240/44:241/44:242/44:243/44:244/44:249/44:253/44:255/44:260/44:261/44:262/44:264/44:265/44:267N/44:270	B*08:01/08:05/08:08N/08:09/08:10/08:15/08:18/08:22/08:24/08:30N/08:39/08:44/08:45/08:46/08:47/08:48/08:50/08:57/08:58/08:59/08:63/08:64/08:66/08:71/08:72N/08:73/08:75/08:76/08:77/08:81/08:83/08:84/08:85/08:86N/08:90/08:91/08:92/08:93/08:96/08:98/08:99/08:100/08:105/08:106/08:109/08:112/08:114/08:118/08:119/08:120/08:124/08:127/08:128/08:134/08:140/08:141/08:142/08:144/08:145/08:147/08:148N/08:149/08:150/08:151/08:152/08:158/08:159/08:160/08:163/08:164/08:166/08:168/08:170/08:172/08:173/08:178/08:182/08:183	B*07:02/07:10/07:15/07:21/07:22/07:23/07:26/07:30/07:35/07:39/07:44N/07:45/07:46/07:49N/07:51/07:52/07:57/07:58/07:59/07:61/07:62/07:67N/07:68/07:73/07:74/07:75/07:76/07:82/07:83/07:86/07:87/07:88/07:89/07:92/07:93/07:94/07:98/07:99/07:101/07:102/07:103/07:104/07:110/07:108/07:109/07:111N/07:113/07:117/07:119/07:127/07:129/07:130/07:132/07:136/07:141/07:142/07:145/07:147/07:150/07:152/07:155/07:156/07:158/07:159/07:160/07:161N/07:164/07:168/07:169/07:170/07:171/07:172/07:173/07:181/07:185/07:188/07:189/07:190/07:191/07:200/07:203/07:205/07:208/07:211/07:212/07:215/07:216/07:217/07:221/07:224/07:226/07:230/07:231N/07:233/07:238/07:24	B*27:03/27:05/27:05Q/27:13/27:17/27:19/27:38/27:47/27:50/27:52/27:53/07:30/07:35/07:39/07:44N/07:45/07:46/07:49N/07:51/07:52/07:57/07:58/27:58/27:60/27:64N/27:70/27:72/74/27:80/27:82/27:84/27:87	B*07:02/07:07/07:09/07:10/07:11/07:15/07:21/07:22/07:23/07:26/07:30/07:35/07:39/07:44N/07:45/07:46/07:49N/07:51/07:52/07:57/07:58/27:58/27:60/27:64N/27:70/27:72/74/27:80/27:82/27:84/27:87
150	Presence or absence of allele B*51.	absence of allele B*51.	presence of allele B*51.	absence of allele B*51.	absence of allele B*51.	
245	B	B*44,-	B*08,*51	B*07,*51	B*07,*15(serological equivalent B62)	
315	B5 (B51, 52)	B*44,-	B*08,*51	B*07,*51	B*07,*15	
331	B*51	B*44,B*44	B*08,B*51	B*07,B*51	B*07,B*15	

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

RESULTS OF PARTICIPATING LABORATORIES

DESPATCHED ON 06TH MARCH 2018

SAMPLES 801-05/2018

Behcet's Disease - interpretive comments (Not Assessed)

Lab No.	801/2018	802/2018	803/2018	804/2018	805/2018
11	The HLA allele associated with Behcet's disease is absent	HLA-B51(5) is associated with but not diagnostic for Behcet's disease	HLA-B51(5) is associated with but not diagnostic for Behcet's disease	The HLA allele associated with Behcet's disease is absent	The HLA allele associated with Behcet's disease is absent
12	This patient is negative for HLA-B*51 (the HLA specificity associated with Behcet's disease). Note: HLA-B*51 alleles with a population frequency <0.001% (identified on http://www.allelefrequencys.net) may not be detected by this assay.	This patient is positive for HLA-B*51 (the HLA specificity associated with Behcet's disease). HLA-B*51 is present in approximately 9% of the Caucasian population.	This patient is positive for HLA-B*51 (the HLA specificity associated with Behcet's disease). HLA-B*51 is present in approximately 9% of the Caucasian population.	This patient is negative for HLA-B*51 (the HLA specificity associated with Behcet's disease). Note: HLA-B*51 alleles with a population frequency <0.001% (identified on http://www.allelefrequencys.net) may not be detected by this assay.	This patient is negative for HLA-B*51 (the HLA specificity associated with Behcet's disease). Note: HLA-B*51 alleles with a population frequency <0.001% (identified on http://www.allelefrequencys.net) may not be detected by this assay.
25	Patient is negative for HLA B51 antigen which is associated with Behcets Disease	The HLA B51 antigen associated with Behcets Disease is present. The presence of a particular HLA antigen does not establish the diagnosis of any particular disease, but provides a probability statement for the possible existence of the disease in the patient.	The HLA B51 antigen associated with Behcets Disease is present. The presence of a particular HLA antigen does not establish the diagnosis of any particular disease, but provides a probability statement for the possible existence of the disease in the patient.	Patient is negative for HLA B51 antigen which is associated with Behcets Disease	Patient is negative for HLA B51 antigen which is associated with Behcets Disease
38	This patient does NOT carry HLA-B*51, which confers susceptibility to Behçet's disease.	This patient carries HLA-B*51 which confers susceptibility to Behçet's disease.	This patient carries HLA-B*51 which confers susceptibility to Behçet's disease.	This patient does NOT carry HLA-B*51, which confers susceptibility to Behçet's disease.	This patient does NOT carry HLA-B*51, which confers susceptibility to Behçet's disease
42	This patient is HLA-B*51 NEGATIVE. Behcet's disease is associated with the expression of the human leukocyte antigen (HLA) class I molecule B51.	This patient is HLA-B*51 POSITIVE. Behcet's disease is associated with the expression of the human leukocyte antigen (HLA) class I molecule B51.	This patient is HLA-B*51 POSITIVE. Behcet's disease is associated with the expression of the human leukocyte antigen (HLA) class I molecule B51.	This patient is HLA-B*51 NEGATIVE. Behcet's disease is associated with the expression of the human leukocyte antigen (HLA) class I molecule B51.	This patient is HLA-B*51 NEGATIVE. Behcet's disease is associated with the expression of the human leukocyte antigen (HLA) class I molecule B51.
150	Absence of B*51 allele.	Presence of B*51 allele.	Presence of B*51 allele.	Absence of B*51 allele.	Absence of B*51 allele.
245	In occidental people, B*51 is present in 2-8% of healthy people and 15% of patients with Behçet's disease. In oriental people, B*51 is present in 20-25% of healthy people and 50-80% of patients with Behçet's disease.	In occidental people, B*51 is present in 2-8% of healthy people and 15% of patients with Behçet's disease. In oriental people, B*51 is present in 20-25% of healthy people and 50-80% of patients with Behçet's disease.	In occidental people, B*51 is present in 2-8% of healthy people and 15% of patients with Behçet's disease. In oriental people, B*51 is present in 20-25% of healthy people and 50-80% of patients with Behçet's disease.	In occidental people, B*51 is present in 2-8% of healthy people and 15% of patients with Behçet's disease. In oriental people, B*51 is present in 20-25% of healthy people and 50-80% of patients with Behçet's disease.	In occidental people, B*51 is present in 2-8% of healthy people and 15% of patients with Behçet's disease. In oriental people, B*51 is present in 20-25% of healthy people and 50-80% of patients with Behçet's disease.
315	B*51 not present	B*51 present	B*51 present	B*51 not present	B*51 not present
331	Absence of B*51	Presence of B*51	Presence of B*51	Absence of B*51	Absence of B*51

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

RESULTS OF PARTICIPATING LABORATORIES

DESPATCHED ON 06TH MARCH 2018

SAMPLES 801-05/2018

Rheumatoid Arthritis results - Assessed

Reference Type For Assessment		801/2018	802/2018	803/2018	804/2018	805/2018	
DRB1*		04:01, 07:01/34/72	03:01/124/132/137, 04:08	11:01/97, 15:01/141	01:03, 13:01/117/190/215	04:04, 11:01/97	
Lab	HLA Alleles of interest	801/2018	802/2018	803/2018	804/2018	805/2018	Comments
113	DRB1*01:01, DRB1*01:02, DRB1*04:01, DRB1*04:04, DRB1*04:05, DRB1*04:08, DRB1*04:09, DRB1*04:10, DRB1*14:02, DRB1*10:01	DRB1*04:01, DRB1*07	DRB1*03, DRB1*04:05/04:08	DRB1*11, DRB1*15	DRB1*01:03, DRB1*13	DRB1*04:04/04:23, DRB1*11	
245	DRB1	DRB1*04,*07	DRB1*03(serological equivalent DR17),*04	DRB1*11,*15	DRB1*01(serological equivalent DR103),*13	DRB1*04,*11	
315	DR 4	DR4, 7	DR 4, 17	DR 11, 15	DR 103, 13	DR 4, 11	
331	DR4	DRB1*04, DRB1*07	DRB1*03, DRB1*04	DRB1*11, DRB1*15	DRB1*01, DRB1*13	DRB1*04,DRB1*11	

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

RESULTS OF PARTICIPATING LABORATORIES

DESPATCHED ON 06TH MARCH 2018

SAMPLES 801-05/2018

Rheumatoid Arthritis - interpretive comments (Not Assessed)

Lab					Comments
No.	801/2018	802/2018	803/2018	804/2018	805/2018
113	Presence of one susceptibility allele for Rheumatoid Arthritis (DRB1*04:01)	Presence of one susceptibility allele for Rheumatoid Arthritis (DRB1*04:05/04:08)	Absence of susceptibility allele for Rheumatoid Arthritis	Absence of susceptibility allele for Rheumatoid Arthritis	Presence of one susceptibility allele for Rheumatoid Arthritis (DRB1*04:04)
245	Presence of a susceptibility allele to rheumatoid arthritis (DRB1*04).	Presence of a susceptibility allele to rheumatoid arthritis (DRB1*04).	Absence of any susceptibility allele for rheumatoid arthritis.	Absence of any susceptibility allele for rheumatoid arthritis.	Presence of a susceptibility allele to rheumatoid arthritis (DRB1*04).
315	DR 4 present	DR 4 present	DR 4 not present	DR 4 not present	DR 4 present
331	Presence of DR4	Presence of DR4	Absence of DR4	Absence of DR4	Presence of DR4

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

RESULTS OF PARTICIPATING LABORATORIES

DESPATCHED ON 06TH MARCH 2018

SAMPLES 801-05/2018

Diabetes results - Assessed

Reference Type For Assessment	801/2018	802/2018	803/2018	804/2018	805/2018	Comments	
DRB1*	04:01, 07:01/34/72	03:01/124/132/137, 04:08	11:01/97, 15:01/141	01:03, 13:01/117/190/215	04:04, 11:01/97		
DQA1*	02:01, 03:03	03:03, 05:01	01:02/11, 05:05	01:03, 05:05	03:01, 05:05		
DQB1*	02:02, 03:01	02:01, 03:01	03:01, 06:02	03:01, 06:03	03:01, 03:02		
Lab							
No.	HLA Alleles of interest	801/2018	802/2018	803/2018	804/2018	805/2018	
113	DRB1*04/DQB1*03:02; DRB1*03:01/DQB1*02:01801	DRB1*07/DQB1*02; DRB1*04:DQB1*03:01	DRB1*03:01/DQB1*02:01; DRB1*04/DQB1*03:01	DRB1*11/DQB1*03; DRB1*15/DQB1*06	DRB1*01:03/DQB1*03; DRB1*13/DQB1*06	DRB1*04/DQB1*03:02/07; DRB1*11/DQB1*03	
129	HLA-DRB1*0401, 0402, 0403, 0404, 0405, 0408 HLA-DQA1*0201, 03, 05 HLA-DQB1*02, 0302, 0303, 04, 0501, 0502, 0503, 0601, 0602, 0603, 0604, 0609	DQA1*0201-DQB1*02 DRB1*0401-DQA1*03-DQB1*0301	DRB1*0408-DQA1*03-DQB1*0301	DQA1*05-DQB1*0301 DQB1*0602	DQA1*05-DQB1*0301 DQB1*0603	DQA1*05-DQB1*0301 DRB1*0404-DQA1*03-DQB1*0302	
154	HLA-DRB1* is typed to the 2-digit level and HLA-DQA1* and HLA-DQB1* are typed to the 4-digit level to detect the following haplotypes : HLA-DRB1*03, DQA1*05:01, DQB1*02:01 and HLA-DRB1*04, DQA1*03:01, DQB1*03:02	HLA-DR typing : HLA-DRB1*04 ; DQB1*07 HLA-DQ typing : HLA-DQA1*02:01 ; DQA1*03:03 HLA-DQB1*02:02 ; DQB1*03:01 Result : haplotype DR3,DQ2 (DRB1*03,DQA1*05:01,DQB1*02:01) : absence haplotype DR4,DQ8 (DRB1*04,DQA1*03:01,DQB1*03:02) : absence	HLA-DR typing : HLA-DRB1*03 ; DQB1*04 HLA-DQ typing : HLA-DQA1*03:03 ; DQA1*05:01 HLA-DQB1*02:01 ; DQB1*03:01 Result : haplotype DR3,DQ2 (DRB1*03,DQA1*05:01,DQB1*02:01) : presence haplotype DR4,DQ8 (DRB1*04,DQA1*03:01,DQB1*03:02) : absence	HLA-DR typing : HLA-DRB1*11 ; DQB1*15 HLA-DQ typing : HLA-DQA1*01:02 ; DQA1*05:05 HLA-DQB1*03:01 ; DQB1*06:02 Result : haplotype DR3,DQ2 (DRB1*03,DQA1*05:01,DQB1*02:01) : absence haplotype DR4,DQ8 (DRB1*04,DQA1*03:01,DQB1*03:02) : absence	HLA-DR typing : HLA-DRB1*01 ; DQB1*13 HLA-DQ typing : HLA-DQA1*03:01 ; DQA1*05:05 HLA-DQB1*03:01 ; DQB1*06:03 Result : haplotype DR3,DQ2 (DRB1*03,DQA1*05:01,DQB1*02:01) : absence haplotype DR4,DQ8 (DRB1*04,DQA1*03:01,DQB1*03:02) : absence	HLA-DR typing : HLA-DRB1*04 ; DQB1*11 HLA-DQ typing : HLA-DQA1*03:01 ; DQA1*05:05 HLA-DQB1*03:01 ; DQB1*03:02 Result : haplotype DR3,DQ2 (DRB1*03,DQA1*05:01,DQB1*02:01) : absence haplotype DR4,DQ8 (DRB1*04,DQA1*03:01,DQB1*03:02) : presence	
245	DRB1 DQA1 DQB1	DRB1*04,*07 DQA1*02,*03 DQB1*02,*03(serological equivalent DQ7)	DRB1*03(serological equivalent DR17),*04 DQA1*03,*05 DQB1*02,*03(serological equivalent DQ7)	DRB1*11,*15 DQA1*01,*05 DQB1*03(serological equivalent DQ7),*06	DRB1*01(serological equivalent DR103),*13 DQA1*01,*05 DQB1*03(serological equivalent DQ7),*06	DRB1*04,*11 DQA1*03,*05 DQB1*03(serological equivalent DQ7),*03(serological equivalent DQ8)	
315	DR 3 DR 4 DQ 8	DR 4, 7 DQ 2, 7	DR 4, 17 DQ 2, 7	DR 11, 15 DQ 6, 7	DR 103, 13 DQ 7, 6	DR4, 11 DQ 7, 8	
331	DR3; DR4	DRB1*04, DRB1*07	DRB1*03, DRB1*04	DRB1*11, DRB1*15	DRB1*01, DRB1*13	DRB1*04,DRB1*11	

UK NEQAS for H&I Scheme 8 - HLA Genotyping for Coeliac and Other HLA Associated Diseases

RESULTS OF PARTICIPATING LABORATORIES

DESPATCHED ON 06TH MARCH 2018

SAMPLES 801-05/2018

Diabetes - interpretive comments (Not Assessed)

Lab					Comments
No.	801/2018	802/2018	803/2018	804/2018	805/2018
113	Absence of susceptibility haplotype for diabetes	Presence of one susceptibility haplotype for diabetes (DRB1*03:01/DQB1*02:01)	Absence of susceptibility haplotype for diabetes	Absence of susceptibility haplotype for diabetes	Presence of one susceptibility haplotype for diabetes (DRB1*04/DQB1*03:02)
129	Neutral	Slightly increased risk	Strongly decreased risk	Strongly decreased risk	Neutral
154	The patient has no HLA haplotype associated with type 1 diabetes. The DR3,DQ2 and DR4,DQ8 haplotypes are found in 95% of type 1 diabetes patients. The HLA-DR3 and DR4 antigens are found 40% of the Caucasian population.	The patient expresses the HLA-DR3,DQ2 haplotype associated with type 1 diabetes. The DR3,DQ2 and DR4,DQ8 haplotypes are found in 95% of type 1 diabetes patients. The HLA-DR3 and DR4 antigens are found 40% of the Caucasian population.	The patient has no HLA haplotype associated with type 1 diabetes. The DR3,DQ2 and DR4,DQ8 haplotypes are found in 95% of type 1 diabetes patients. The HLA-DR3 and DR4 antigens are found 40% of the Caucasian population.	The patient has no HLA haplotype associated with type 1 diabetes. The DR3,DQ2 and DR4,DQ8 haplotypes are found in 95% of type 1 diabetes patients. The HLA-DR3 and DR4 antigens are found 40% of the Caucasian population.	The patient expresses the HLA-DR4,DQ8 haplotype associated with type 1 diabetes. The DR3,DQ2 and DR4,DQ8 haplotypes are found in 95% of type 1 diabetes patients. The HLA-DR3 and DR4 antigens are found 40% of the Caucasian population.
245	Combination class II HLA DRB1*04/DRB1*07 (DR4/DR7) protective for type I autoimmune diabetes, because here DR4 is associated to DQ7.	Combination class II HLA DRB1*03/DRB1*04 (DR3/DR4) susceptible for type I autoimmune diabetes.	Combination class II HLA DRB1*11/DRB1*15 (DR5/DR2) protective for type I autoimmune diabetes.	Combination class II HLA DRB1*01/DRB1*13 (DR1/DR6) protective for type I autoimmune diabetes.	Association of a susceptibility haplotype for type I autoimmune diabetes (DR4/DQ8) with a protective haplotype (DR11/DQ7).
315	DR 4 present DQ 8 not present	DR 4 present DQ 8 not present	DR 4 not present DQ 8 not present	DR 4 not present DQ 8 not present	DR 4 present DQ 8 present
331	Absence of DR3 ; Presence of DR4	Presence of DR3 ; Presence of DR4	Absence of DR3 ; Absence of DR4	Absence of DR3 ; Absence of DR4	Absence of DR3 ; Presence of DR4